WO2002043731A2 - Treatments for neurogenetic disorders, impulse control disorders, and wound healing - Google Patents

Treatments for neurogenetic disorders, impulse control disorders, and wound healing Download PDF

Info

Publication number
WO2002043731A2
WO2002043731A2 PCT/US2001/044923 US0144923W WO0243731A2 WO 2002043731 A2 WO2002043731 A2 WO 2002043731A2 US 0144923 W US0144923 W US 0144923W WO 0243731 A2 WO0243731 A2 WO 0243731A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
different
same
topiramate
Prior art date
Application number
PCT/US2001/044923
Other languages
French (fr)
Other versions
WO2002043731A3 (en
WO2002043731B1 (en
Inventor
Nathan Andrew Shapira
Mary Catherine Lessig
Daniel John Driscoll
Original Assignee
University Of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Florida filed Critical University Of Florida
Priority to EP01996012A priority Critical patent/EP1345602B1/en
Priority to AU2002227052A priority patent/AU2002227052A1/en
Priority to CA002430010A priority patent/CA2430010A1/en
Priority to DE60142632T priority patent/DE60142632D1/en
Priority to AT01996012T priority patent/ATE474572T1/en
Publication of WO2002043731A2 publication Critical patent/WO2002043731A2/en
Publication of WO2002043731A3 publication Critical patent/WO2002043731A3/en
Publication of WO2002043731B1 publication Critical patent/WO2002043731B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Definitions

  • Hereditary ataxias and related disorders such as Friedreich ataxia, ataxia telangiectasia, olivopontine cerebellar degeneration, Ramsay Hunt syndrome, abetalipoproteinemia, Machado-Joseph disease, and familial spastic paraparesis;
  • Movement disorders such as Juvenile Huntington disease, the dystonias including blepharospasm and spasmodic torticolis, tremor, myoclonus, and Hallervorden-Spatz disease;
  • Phakomatoses, or neurocutaneous syndromes such as neurof ⁇ bromatosis, tuberous sclerosis, Sturge-Weber, and Von Hippel-Landau disease
  • Mitochondrial encephalomyopathies such as the MELAS syndrome, Kearns-Sayre, and Leigh disease
  • Hereditary disorders of nerve and muscle such as infantile spinal muscular atrophy, Charcot-Marie-Tooth disease
  • ADHD affects about 4% to 6% of the U.S. population. ADHD is not limited to children and is a chronic lifetime disease. Approximately one-half to two-thirds of children with ADHD will continue to have significant problems in adulthood and experience difficulties which impact employment, familial, and social relationships.
  • some common symptoms of ADHD include: (1) often fails to give close attention to details or makes careless mistakes; (2) often has difficulty sustaining attention to tasks; (3) often does not seem to listen when spoken to directly; (4) often fails to follow instructions carefully and completely; (5) losing or forgetting important things; (6) feeling restless, often fidgeting with hands or feet, or squirming; (7) running or climbing excessively; (8) often talks excessively; (9) often blurts out answers before hearing the whole question; and (10) often has difficulty awaiting turn. It should be kept in mind that the exact nature and severity of ADHD symptoms varies from person to person however. Approximately one-third of people with ADHD do not have the hyperactive or overactive behavior component.
  • Carbamazepine (Tegretol) has been reported to be useful for the treatment of patients experiencing sudden confusion and depression. Within weeks of initiating treatment, the patients experienced fewer incidences of sudden confusion and depression, and an increase in attention and focus. Persinger, M.A., "Subjective improvement following treatment with carbamazepine (Tegretol) for a subpopulation of patients with traumatic brain injuries", Percept Mot Skills 90:37-40 (2000). Carbamazepine has also been shown to be effective in treating children with features of ADHD.
  • PWS Prader-Willi Syndrome
  • infantile hypotonia characterized by infantile hypotonia, mental retardation, short stature, hypogonadism, dysmorphic features, and hyperphagia with a high risk of obesity.
  • behavioral and psychiatric manifestations include self-injury (e.g. gouging, nail biting, and skin picking), explosive outbursts, oppositional behavior, obsessive ruminations, and compulsive behaviors including hoarding, counting, and arranging.
  • PWS is typically a sporadic condition, which usually results from a deletion in chromosome 15ql l- ql3 or maternal uniparental disomy of chromosome 15.
  • Driscoll, D.J.; Thomas, P.Y.; Nicholls, R.D. "Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes", MolHum Reprod 3:321-332 (1997).
  • PWS is also a relatively common genetic condition with an estimated prevalence of approximately 1/10,000 to 1/25,000.
  • Driscoll, D.J.; Thomas, P.Y.; Nicholls, R.D. "Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes", Mol Hum Reprod 3:321-332 (1997).
  • PSP Pathological skin picking
  • PSP is often considered an obsessive compulsive spectrum disorder (Goldsmith, T.D.; Shapira, N.A.; Phillips, K.A.; et al, "Obsessive Compulsive Spectrum Disorders”; in: Swinson, R.P.; Antony, M.M.; Rachman, S.; Richter, M.A.
  • the subject invention has, surprisingly, found improvements in impulsivity control, without negative effects on attention and concentration, in patients treated with topiramate. These observations are unexpected and novel.
  • the subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use.
  • the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V.
  • the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V.
  • compositions are administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury.
  • the invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.
  • Figures 1, 3, 5, and 7 depict the efficiency ratios of patients treated with topiramate as measured by the Delay Task of the Gordon Diagnostic.
  • Figures 2, 4, 6, and 8 depict the total correct responses of patients treated with topiramate as measured by the Vigilance Task of the Gordon Diagnostic.
  • Figures 9A-D and 10A-C depict the progression of wound healing in patients treated with topiramate.
  • Figures 11A-B Photographs of improvement in wound healing for Ms. A on topiramate (75 mg/day) at week 4 ( Figure 11 A) and 150 mg/day topiramate at week 8 ( Figure 1 IB).
  • Figures 12A-B Photographs of improvement for Mr. B. Mr. B. on 25 mg/day topiramate ( Figure 12A), Week 1; Mr. B. on 200 mg/day topiramate ( Figure 12B), Week 8.
  • Figures 13A-B Photographs of primary SIB lesions. Ms. C. (right breast), baseline ( Figure 13 A); Ms. C. on 175 mg/day (right breast), Week 8 ( Figure 13B).
  • Figure 14 Number of ulcerated SIB lesions for Ms. C. as documented by group home staff utilizing systematic full body surveys (* denotes lesions smaller than previous lesions and appearing to result after insect bites).
  • Figures 15A-B Photographic record of Ms. A hair loss at start of treatment ( Figure 15 A) and during treatment ( Figure 15B).
  • Figure 16 illustrates the reported reduction in the urge of Ms. A to pull hair.
  • Figure 17 represents the improvement in impulse control for Ms. A during treatment using the Gordon Diagnostic System.
  • Figure 18 illustrates that Ms. A suffered no significant change in cognitive ability during treatment.
  • the subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use.
  • an individual is treated in methods comprising the administration of therapeutically effective amounts of compositions comprising compounds selected from the group consisting of formulas I-V.
  • therapeutically effective amounts of topiramate are administered to individuals topically or orally.
  • compositions comprising one or more of the compounds disclosed in fonnulas I-V are administered for the control or treatment neurogenetic disorders.
  • the neurogenetic disorders include PWS and ADHD.
  • the subject invention provides methods and compositions for the treatment or control of ADHD or PWS.
  • the subject invention provides methods for controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V.
  • One embodiment of the invention provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V and acceptable carriers.
  • the subject invention provides methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V to an individual having a wound.
  • compositions are topically administered to a wound.
  • the compositions may take the form of a salve, ointment, or aerosol applied to the site of injury.
  • the compositions may be administered to the wound site as a component of a bandage or transdermal patch. In these instances, the compositions may be an integral component of the bandage or transdermal patch and are thereby applied to the wound site.
  • therapeutically effective amounts of the compounds comprising formulas I-V are incorporated into bioadhesive compositions useful in wound closure.
  • therapeutically effective amounts compositions comprising the compounds of formulas I-V are administered orally.
  • the subject invention provides methods of promoting wound healing or controlling impulsive behavior in an individual
  • the subject invention provides methods having both human and veterinary utility.
  • the term "individual” includes animals of avian, mammalian, or reptilian origin. Mammalian species which benefit from the disclosed methods include, and are not limited to, apes, chimpanzees, orangutans, humans, monkeys; domesticated animals (pets) such as dogs, cats, guinea pigs, hamsters, Vietnamese pot-bellied pigs, rabbits, and ferrets; domesticated farm animals such as cows, buffalo, bison, horses, donkey, swine, sheep, and goats; exotic animals typically found in zoos, such as bear, lions, tigers, panthers, elephants, hippopotamus, rhinoceros, giraffes, antelopes, sloth, gazelles, zebras, wildebeests, prairie dogs, koala
  • Reptiles include, and are not limited to, alligators, crocodiles, turtles, tortoises, snakes, iguanas, and/or other lizards.
  • Avian species include, and are not limited to, chickens, turkeys, pigeons, quail, parrots, macaws, dove, Guinea hens, lovebirds, parakeets, flamingos, eagles, hawks, falcons, condor, ostriches, peacocks, ducks, and swans. Therefore, the subject invention provides methods of controlling the impulse of an individual to scratch, pick, lick, or otherwise cause self-injury by repeated mechanical irritation of an injured area.
  • Bioadhesives incorporating materials to promote wound healing are well known in the art (see, for example, U.S. Patent Nos.
  • Compounds of formulas I-V are anti-epileptic compounds, which are highly effective anti-convulsants.
  • the compounds useful in the practice of the instant invention include the individual isomers, analogs, and homologs of the disclosed anti-convulsant compounds. Racemic mixtures, as well as the isolated enantiomeric forms, of the compounds can also be used in the practice of the subject invention.
  • the compounds useful for the practice of the subject invention include pharmaceutically acceptable salts, for example; alkali metal salts, such as sodium or potassium, ammonium salts, dialkyammonium salts, trialkylammonium salts, tetraalkylammonium salts, and tromethamine salts. Hydrates and other solvates of the compounds are also included within the scope of the compounds useful in the practice of this invention.
  • Xi is CH 2 or oxygen
  • Ri is hydrogen or alkyl
  • R 2 , R 3 , R , and R 5 are independently hydrogen or lower alkyl and, when X] is CH 2 , R 4 , and R 5 may be alkene groups joined to form a benzene ring and, when Xi is oxygen, R 2 and R 3 and/or * and R 5 together may be a methylenedioxy group of the following formula:
  • R 6 and R are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
  • R may be hydrogen or an alkyl of about 1 to 4 carbons, such as methyl, ethyl, and isopropyl.
  • Alkyl includes straight and branched chain alkyl.
  • Alkyl groups for R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are of about 1 to 3 carbons and include methyl, ethyl, isopropyl and N-propyl.
  • Xi is oxygen and both R 2 and R 3 and 4 and R5 together are methylenedioxy groups of the formula wherein R 6 and R 7 are both hydrogen, both alkyl or combine to form a spiro cyclopentyl or cyclohexyl ring, in particularly where R 6 and R 7 are both alkyl such as methyl.
  • Xi is CH 2 and 4 and R 5 are joined to form a benzene ring.
  • Another embodiment provides compounds of formula (I) wherein both R 2 and R 3 are hydrogen.
  • R 6 and R 7 may be the same or different and are selected from any of hydrogen or Ci to C 4 alkyl. In one embodiment, R 6 and R 7 are each hydrogen.
  • R 8 and R 9 may be the same or different and are selected from any of hydrogen or Ci to C 4 alkyl. In one embodiment, R and R 9 are each Cj to C 4 alkyl.
  • Rio and Ri i may be the same or different and are selected from any of azido, halogen, hydroxyl, sulfamoyl (H 2 NS0 2 0), Ci to C 4 alkoxy, Ci to C alkyl thiocarbonate (RSC(O)O), Ci to C 4 alkyl carbonate (ROC(O)O), or Ci to C 4 alkyl carboxylate (RC(O)O), wherein R is Ci to C alkyl.
  • Rio and Rn are selected from any of CpC alkyl thiocarbonate, halogen or hydroxyl.
  • alkyl and alkoxy include straight and branched chains.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, n- butyl, isobutyl, and t-butyl.
  • Halogen includes bromine, chlorine, fluoride and iodine.
  • Preferred compounds of the formula (II) are those wherein the pyran ring is in the L-sorbopyranose absolute configuration.
  • Particularly preferred compounds of formula (II) are those wherein the pyran ring is in the L-sorbopyranose absolute configuration, R 6 and R are each hydrogen, R 8 and R 9 are each methyl; Rio is methyl thiocarbonate (CH 3 SC(0)0) and Rn is halogen; or Rio and Rn are both halogen; or Rio is hydroxyl and Rn is halogen.
  • Particularly preferred halogens include bromine, chlorine, and iodine.
  • compounds of formula (II) are: (1) 5-deoxy-5-iodo- 2,3-0-(l-methylethylidene)-4-[methylthiocarbonyl)]- ⁇ -L-sorbopyranose sulfamate, (i.e., where the compound is in the L-sorbopyranose absolute configuration, Re and R 7 are hydrogen, R 8 and R 9 are methyl, Rio is CH 3 SC(0)0, and Rn is iodine); (2) 4,5-dibromo-4,5- dideoxy-2,3-0-(l-methylethylidene)- ⁇ -L-sorbopyranose sulfamate, (i.e., where the compound is in the L-sorbopyranose absolute configuration, R 6 and R 7 are hydrogen, R 8 and R 9 are ' methyl, R ⁇ 0 and Rn are bromine); and (3) 5-chloro-5-deoxy-2,3-0-(l- methylethylidene)- ⁇ -L-
  • R ⁇ 2 and R ⁇ 3 are the same or different and are selected from any of hydrogen, alkyl ( to C 6 ), cycloalkyl (C 3 -C 7 ), allyl, or benzyl.
  • R ⁇ 2 and Rn are each hydrogen.
  • R ⁇ 4 and R 15 are the same or different and selected from hydrogen or lower alkyl.
  • X 2 may be chosen from carbon (C) or sulfur (S), with the stipulation that when X 2 is carbon, R ⁇ 6 and R ⁇ 7 are the same or different and are selected from hydrogen or lower alkyl, whereas when X 2 is sulfur one of R ⁇ 6 and R] 7 is oxygen and the other is a lone pair of electrons or both R ⁇ 6 and Rn are oxygen.
  • alkyl includes straight and branched chains.
  • alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, and t-butyl.
  • Particularly preferred compounds of formula III are: (1) (1R,2R,3S,4S)- (l,2:3,4-di-0-methylethylidenecyclohexan-l,2,3,4-tetraol-r-yl)methyl sulfamate, (i.e., where R ]2 and R ⁇ 3 are hydrogen, R ⁇ 4 , R 15 , R ⁇ 6 , and R ⁇ 7 are methyl and X 2 is carbon); (2) ( 1 R,2S,3 S,4S)-(3 ,4-O-methylethylidene- 1 ,2-O-sulfonyl-cyclohexan- 1 ,2,3,4-tetraol-4-yl) methyl sulfamate, (i.e., where R i2 and R ⁇ 3 are hydrogen, R !4 and R ]5 are methyl, R ⁇ 6 is oxygen and R ]7 is an electron pair and X 2 is sulfur); and (3) (l)-(
  • Another compound useful in the subject invention is
  • AR is represented by the following formulas:
  • Y is selected from the group consisting of halogens such as F, Cl, Br and I, or trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; when X 3 , which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms.
  • R ⁇ 8 , R ⁇ , R 20 , and R21 may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NR ⁇ 8 R ⁇ and NR 2 oR 2 ⁇ , identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom.
  • Compositions useful in the practice of this invention comprise one or more of the compounds of formulas I-V admixed with a pharmaceutical carrier.
  • the compositions may be made according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., injection, oral, suppository, topical, or parenteral.
  • any of the usual pharmaceutical media may be employed.
  • suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
  • suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed.
  • tablets may be sugar coated or enteric coated by standard techniques.
  • Suppositories may be prepared, in which case cocoa butter could be used as the carrier.
  • the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • compositions useful in the practice of the subject invention include salves, cosmetics, ointments, and the like. Such compositions may be topically applied to a site or incorporated into articles of manufacture including, but not limited to, bandages, adhesive strips for the covering of wounds (e.g., BAND AID brand adhesive strips), or transdermal patches. Carriers such as cocoa butter, viscous polyethylene glycols, hydrogenated oils, and such mixtures can be emulsified if desired.
  • Compounds of the subject invention may also be incorporated into cosmetics. Additional materials and substances suitable as carriers for the compounds of formulas I-V are described in the International Cosmetic Ingredient Dictionary and Handbook, 8 th Edition (The Cosmetic, Toiletry, and Fragrance Association (CTFA), 2000), hereby incorporated by reference in its entirety.
  • CTFA Cosmetic, Toiletry, and Fragrance Association
  • the active ingredients can be packaged in pressurized aerosol containers with a propellant, e.g., carbon dioxide, nitrogen, propane, etc. with the usual adjuvants such as cosolvents, wetting agents, etc.
  • a propellant e.g., carbon dioxide, nitrogen, propane, etc.
  • adjuvants such as cosolvents, wetting agents, etc.
  • compositions comprise, as an inactive ingredient, an effective amount of one or more non-toxic, pharmaceutically acceptable ingredient(s).
  • ingredients for use in the compositions include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, calcium carbonate, talc, flour, and equivalent non-toxic carriers and diluents.
  • compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository, bandage, and the like, from about 0.1 to about 400 mg of the active ingredient.
  • the compositions comprise about lOmg to 200 mg per dosage unit.
  • the compositions contain comprise about 20mg to about lOOmg of active ingredient.
  • the compositions comprise about 25mg of active ingredient per unit dose.
  • Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent.
  • the tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methyl cellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.
  • the Delay Task requires that the subject inhibit responding (pressing a button and then refraining from pressing the button again for at least 6 seconds) in order to earn points.
  • the Delay Task measures the subject's ability to suppress and delay impulsive behavioral responses. While focusing and sustaining attention usually facilitate Delay Task performance, the Delay Task maximally draws on a subject's ability to inhibit impulsive responses.
  • the Delay Task's total efficiency ratio (EF) is considered the best indicator (score ranges from 0 to 1) of the level of impulsivity with the lower the score (such as less than .5) indicating higher impulsivity and poor self-control.
  • the Vigilance Task measures the subject's ability to focus attention on a task and to maintain this attention over a period of time without reinforcement.
  • the correct responses (CR) of the Vigilance Task measures the level of alertness and is a measure of the subjects attentional processes.
  • JAS-002 (patient Number 2) had a baseline total efficiency ratio (ER) of 0.02, approximately 8 standard deviations below the normal range and well below the first percentile in regards to the Delay task. This falls markedly within the range of an "abnormal" performance as stated in the rating score manual provided by the manufacturer of the GDS.
  • ER total efficiency ratio
  • JAS-002 demonstrated dramatic improvement in ER (a value of 0.98), well within the normal range of performance.
  • JAS-002 continued with improvements in ER (a value of 0.85), within the normal range of performance. Attention as evaluated by the Vigilance Task for JAS-002 showed essentially no change for CR from 39 at baseline to 38 (at a dose of 175 mg/day) at 2 months.
  • MJG-001 For patient Number 1 (MJG-001), a significant improvement has been noted. At baseline, MJG-001's ER for the Delay Task was at a value of 0.06 (approximately 7 standard deviations below the average ER) demonstrating a severe impairment of impulsivity. However, at the second testing session, MJG-001 showed moderate improvement with a Delay Task ER of 0.24. At visit 5, approximately 1.5 months after starting medication (at a dose of 75 mg/day), MJG-001 demonstrated a substantial improvement with an ER value of 0.46 and two weeks later (at a dose of 125 mg/day) had an ER value of 0.70.
  • MJG-001 demonstrated a substantial improvement with an ER value of 0.50.
  • the Vigilance Task for MJG-001 showed some variability up and down during the study and, after approximately 2 months, showed a mild decrease of CR from 43 to 41 (at a dose of 150 mg/day).
  • Patient Number 3 (GFV-003) has also shown a severe deficit in impulsivity and focusing; baseline ER was 0.02 (a value 8 standard deviations below the normal range).
  • baseline ER was 0.02 (a value 8 standard deviations below the normal range).
  • GFV-003 had improved to an 0.09 ER and by week 4 (at a dose of 100 mg/day) to an ER of 0.19, and by 2 months (at a dose of 200 mg/day) the ER was at 0.10.
  • the Vigilance Task for GFV-003 showed variability on topiramate and by the end of two months was essentially unchanged with a CR decreasing from 16 at baseline to 15 at 2 months.
  • topiramate for impulsivity, without negative effects on attention and concentration, is both novel and clinically applicable.
  • Disorders with impulsivity and deficits in attention and concentration are difficult to manage for both the patient and their caregiver, especially in cases of dementia.
  • Impulsivity and lack of concentration can severely handicap day-to-day functioning in all age groups affected by these disorders.
  • Patient #3 (GFV-003) also has pathologic skin picking (PSP) in addition to food seeking behavior.
  • PSP pathologic skin picking
  • Patient #3 has a chronic large lesion on his lower left arm.
  • topiramate 25 mg/day
  • the 4 th week on topiramate at 100 mg/day
  • the lesion on his lower left arm had completely healed over.
  • the progression of wound healing is provided in Figures 9A-D and 12A-B.
  • Patient #1 has pathologic skin picking (PSP) in addition to food seeking behavior.
  • PSP pathologic skin picking
  • several large lesions (where she skin picks) on her right arm, legs, and lips were clearing up quickly (within 5 days) after topiramate was initiated at 25 mg/day.
  • the patient has continued to do well in terms of skin clearing.
  • a large lesion on her right arm completely healed over after about 2 months on topiramate (at a dose of 125 mg/day).
  • the progression of wound healing is provided in Figures 10A-C and 11A-B.
  • topiramate for PSP and related disorders is also novel and clinically applicable.
  • pathologic skin picking also referred to as neurotic excoriation, repetitive skin picking, compulsive skin picking, and dermatotillomania
  • obsessive-compulsive spectrum disorders t.e., repetitive self-mutilation (RSM), oncophagia, rhinotillxomania, trichotillomania
  • RSM repetitive self-mutilation
  • Screening measures included a physical examination, psychiatric background, medication history, blood draw for laboratory assessment (CBC, SMA-12, urinalysis, and a B-hCG for women of childbearing potential), and the Structured Clinical Interview for DSM- IV, Patient Edition (SCID-P). Weekly assessments of weight loss, participant functioning, and safety measures including blood pressure and pulse were taken by the investigators at each visit. Participants are residents of group homes operated by the Association of Retarded citizens, Alachua County, Florida (ARC). These homes are monitored, thereby allowing recording of participants' behavioral and psychiatric manifestations as well as their medication management. Participants began pharmacotherapy with topiramate at 25 mg of drug given in the evening for 7 days. After 14 days, their daily dose could be increased in increments of up to 50 mg/week for the next 6 weeks.
  • Case 1 Ms. A. is a 19 year-old female who through DNA methylation testing was positive for PWS and shown to have a chromosomal deletion through FISH and DNA polymorphism analyses. Ms. A. has a history of hoarding and severe skin picking dating to childhood. Current concomitant psychiatric medications include fiuoxetine 60 mg/day and naltrexone 50 mg/day. Psychiatric intervention dated back to 1992 when the subject began therapy with clomipramine and fenfluramine, both of which were unsuccessful in managing her behavior and weight problem.
  • Case 2 Mr. B. is a 29 year-old male confirmed to be a chromosomal deletion as described above. He has a history of severe food seeking and skin picking dating to childhood. Mr. B does not have a history of taking psychotropic medications and had declined a previous recommendation to take fiuoxetine. Initial healing of his primary lesion (a round 1.5cm diameter ulcerated lesion) was noted within one week of initiating topiramate freatment (25mg/day) at which point photographic records were started. Mr. B also experienced some increased irritability when topiramate was initiated. Irritability returned towards baseline by Week 8. Mr. B also experienced a decrease in his weight from 180.0 lbs at baseline to 176.8 lbs at Week 8.
  • Case 3 Ms. C. is a 32 year-old female confirmed to be a chromosomal deletion. Concomitant psychotropic medications include fiuoxetine 20mg/day. She has a history of food seeking and skin picking dating to childhood. Due to her employment, Ms. C. picks in multiple concealed locations (e.g., her chest, breasts, and the top of her legs). Because of her secrecy regarding SIB, the staff members of her group home daily perform full body surveys. As a result of previous experience with Ms. A and Mr. B, photographic records of her lesions were started prior to initiation of topiramate ( Figure 13).
  • Topiramate is able to attenuate self-injurious behavior in a patient population where SIB is common and difficult to manage and treat. All three subjects have longstanding histories of self-injury, and two subjects (Ms. A. and C.) had failed previous psychotropic medication interventions. Furthermore, all three PWS subjects have chosen to continue on topiramate after the 8-week trial (8 months for Ms. A., 7 months for Mr. B., and 4 months for Ms. C.) with continued improvement in self-injury. Improvement in self-injury was noted by both investigators and in systematic body evaluations by the group home in one subject (Ms. C). Additionally, while individuals with PWS often pick surreptitiously and pick even when they describe having no urges, all three subjects reported decreased urges to pick while on topiramate.
  • Canine acral lick dermatitis is a common self-inflicted skin disorder in dogs in which localized alopecia and epidermal hyperplasia and fibrosis are caused by continued licking, biting, and/or scratching one or more areas usually near the carpus or hock.
  • ALD acral lick dermatitis
  • lick granuloma acral pruritic nodule
  • neurodermatitis is a common self-inflicted skin disorder in dogs in which localized alopecia and epidermal hyperplasia and fibrosis are caused by continued licking, biting, and/or scratching one or more areas usually near the carpus or hock.
  • the licking of the paws or flank causes significant local trauma and, in extreme cases, may require surgery and steroids. Occasionally, the animal must be put to death because of chronic ulceration or osteomyelitis.
  • ALD etiology of ALD
  • ALD etiology of ALD
  • Certain large breeds appear to be more susceptible, such as German Shepherds, Labrador Retrievers, and Great Danes.
  • the repetitive self-licking, chewing, or scratching creates areas of hair loss and the production of lesions which may range in size from several centimeters to the entire surface of the limb. This stereotypic behavior prevents the lesions from healing and may cause discomfort, pain and, in severe cases, may prove crippling.
  • a double-blind placebo-controlled trial of 8 weeks duration (6 week treatment and 2 week taper) will be conducted.
  • One-half of the dogs receive placebo.
  • the dogs will start at 2 mg/kg in a split dose (1 mg/kg twice a day) for the first two weeks.
  • the dose will be increased 2 mg/kg a week as tolerated for the next four weeks.
  • the maximum dosage will not exceed 10 mg/kg.
  • This dosage strategy is based upon the target dose for seizures, which is 5 to 10 mg/kg in split doses.
  • Topiramate or placebo will be administered via gelatin capsules once daily (5 minutes before feeding). Owners will be instructed to avoid feeding dogs anything in addition to their regular diet. In addition to adhering to the dogs' routine (e.g., food, exercise, and training), owners will also be asked to maintain environmental conditions for the duration of the study.
  • a video camera will record the dogs' behavior for 1 hour each week for the 6 weeks of the trial.
  • the primary behavior of interest is self-licking or self-chewing of the granulomatous lesion.
  • the measure of time the dogs are involved in licking or chewing will be computerized.
  • the evaluator will press the designated key when the dog's tongue or lips first makes contact with the lesion, and at the end of a continuous bout of licking or chewing when the dog lifts its head from the lesion and transfers its attention elsewhere.
  • a 2-week taper period will follow the 6-week treatment period. During week 7, study medication will be reduced by approximately 25% for 3 days. On day 4, the dosage will be reduced by another 25%. On day 11 the remaining dose will be reduced in half again and on day 13 all study medication will be stopped. The dogs' last visit will be day 14 of the taper period.
  • Topiramate was used as an adjunct therapy in a 38 year-old female with a 9- year history of trichotillomania. She was on a stable dose combination of fluvoxamine and clomipramine. While the fluvoxamine/clomipramine combination was therapeutic for 3 years, 6 months ago Ms. A experienced an increase in hair pulling predominately on the left side of her head. The investigators have made photographic records of Ms. A.'s hair loss ( Figures 15A-B) and she has been evaluated psychometrically for impulse control. Ms. A was started on a 25mg dose of topiramate at night and was gradually titrated in increments of 25mg to 150mg at night. Preliminary results suggest the addition of topiramate to this combination therapy effective for trichotillomania.
  • the patient has continued to see a reduction in the urge to, as well as in the time spent, pull her hair. Re-growth of hair at the sites previously pulled has also been observed.
  • the patient is currently on 475 mg topiramate (p.o. q.h.s.).

Abstract

The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptons associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V.

Description

DESCRIPTION
TREATMENTS FOR NEUROGENETIC DISORDERS,
IMPULSE CONTROL DISORDERS. AND WOUND
HEALING
Cross-Reference to Related Application The present claims the benefit of U.S. Provisional Application No. 60/250,113, filed November 30, 2000, which is hereby incorporated by reference herein in its entirety, including any figures, tables, or drawings.
Background of the Invention
[0001] As many as one-third of the approximate 3,000 known genetic disorders are believed to have important neurological involvement. Individually, most genetic disorders are of low incidence in the general population; however, collectively they represent an enormous burden on affected individuals, their families, and society. Many neurogenetic disorders manifest themselves early in life leading to either a premature death or to lifelong disability with significant attendant psychological and economic hardships.
[0002] Examples of these types of disorders include: (1) Hereditary ataxias and related disorders such as Friedreich ataxia, ataxia telangiectasia, olivopontine cerebellar degeneration, Ramsay Hunt syndrome, abetalipoproteinemia, Machado-Joseph disease, and familial spastic paraparesis; (2) Movement disorders such as Juvenile Huntington disease, the dystonias including blepharospasm and spasmodic torticolis, tremor, myoclonus, and Hallervorden-Spatz disease; (3) Phakomatoses, or neurocutaneous syndromes such as neurofϊbromatosis, tuberous sclerosis, Sturge-Weber, and Von Hippel-Landau disease; (4) Mitochondrial encephalomyopathies such as the MELAS syndrome, Kearns-Sayre, and Leigh disease; (5) Hereditary disorders of nerve and muscle such as infantile spinal muscular atrophy, Charcot-Marie-Tooth disease, hereditary sensory and autonomic neuropathies, genetic myasthenic syndromes, metabolic myopathies, muscular dystrophies, and myotonias.
[0003] There are numerous other neurological disorders that are also believed to result from genetic abnormalities such as the Laurence-Moon-Bardet-Biedl, Aicardi, Sjogren- Larsson, Prader-Willi and Angelman syndromes. [0004] In addition to those diseases that have a recognizable pattern of inheritance, there are many other neurological disorders that seem to have, in some cases, a familial basis. These may well represent neurogenetic disorders with multifactorial etiology. Such diseases can be as diverse as disorders of defective cellular migration (such as lissencephaly, heterotopias), neural tube defects, congenital hydrocephalus, myoclonic epilepsy, attention deficit hyperactivity disorder (ADHD), and narcolepsy.
[0005] It is estimated that ADHD affects about 4% to 6% of the U.S. population. ADHD is not limited to children and is a chronic lifetime disease. Approximately one-half to two-thirds of children with ADHD will continue to have significant problems in adulthood and experience difficulties which impact employment, familial, and social relationships.
[0006] According to the DSM-IV (the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) some common symptoms of ADHD include: (1) often fails to give close attention to details or makes careless mistakes; (2) often has difficulty sustaining attention to tasks; (3) often does not seem to listen when spoken to directly; (4) often fails to follow instructions carefully and completely; (5) losing or forgetting important things; (6) feeling restless, often fidgeting with hands or feet, or squirming; (7) running or climbing excessively; (8) often talks excessively; (9) often blurts out answers before hearing the whole question; and (10) often has difficulty awaiting turn. It should be kept in mind that the exact nature and severity of ADHD symptoms varies from person to person however. Approximately one-third of people with ADHD do not have the hyperactive or overactive behavior component.
[0007] To meet diagnostic criteria, these behaviors must be excessive, long-term, and pervasive. The behaviors must appear before age 7, and continue for at least 6 months. A crucial element requires that the behaviors must create a real handicap in at least two areas of a person's life, such as school, home, work, or social settings. These criteria set ADHD apart from the "normal" distractibility and impulsive behavior of childhood, or the effects of the hectic and overstressed lifestyle prevalent in our society.
[0008] There are no reports in the literature of topiramate specifically used to treat deficits in attention and concentration. Carbamazepine (Tegretol) has been reported to be useful for the treatment of patients experiencing sudden confusion and depression. Within weeks of initiating treatment, the patients experienced fewer incidences of sudden confusion and depression, and an increase in attention and focus. Persinger, M.A., "Subjective improvement following treatment with carbamazepine (Tegretol) for a subpopulation of patients with traumatic brain injuries", Percept Mot Skills 90:37-40 (2000). Carbamazepine has also been shown to be effective in treating children with features of ADHD. Silva, R.R.; Munoz, D.M.; Alpert, M., "Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis", J Am Acad Child Adolesc Psychiatry 35:352-358 (1996). In some patients, with or without intellectual disability, being treated for refractory partial epilepsy, gabapentin is an equally effective add-on medication. Mikati, M.A.; Choueri, R; Khurana, D.S.; et al., "Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability", J Intellect Disabil Res 42:57-62 (suppl. 1, 1998). Three dementia patients are noted in the literature to have received topiramate in a retrospective chart review of 58 consecutive psychiatric patients receiving topiramate. Marcotte, D., "Use of topiramate, a new anti-epileptic as a mood stabilizer", J Affect Disorder 50:245-251 (1998). "Improvement" was rated by a Likert scale from 'worse,' to 'no change,' to 'minimally improved,' to 'moderately improved,' to 'markedly improved.' The three patients with dementia are described to have 'moderate' or 'marked' improvement when on topiramate. The author of this chart review hypothesized that topiramate may have some anti-psychotic effect.
[0009] While there have been no reported efforts to use topiramate for the treatment of impulsivity, there have been a limited number of publications reporting the effects of anti-convulsant treatment on impulsivity (or measures of impulsivity). These references tend to show no change or worsening of impulsivity with anti-convulsant treatment. For example, one large study showed no overall effect on measures of impulsivity of anti-convulsant medication in epileptic children (Mitchell, W.G.; Zhou, Y.; Chavez, J.M.; Guzman, B.L., "Reaction time, attention, and impulsivity in epilepsy", Pediatr Neurol 8:19- 24 (1992)) and another large study showed, at higher total serum levels of anti-convulsant medication in children with epilepsy, more impulsive errors on complex reaction time testing (Mitchell, W.G.; Zhou. Y.; Chavez, J.M.; Guzman, B.L., "Effects of anti-epileptic drugs on reaction time, attention, and impulsivity in children", Pediatrics 91 :101-105 (1993)). It is notable that both of these studies focused on children with epilepsy.
[0010] A case report from 1987 described carbamazepine being useful for intermittent explosive disorder in a patient with Prader-Willi Syndrome (Gupta, B.K.; Fish, D.N.; Yerevanian, B.I., "Carbamazepine for intermittent explosive disorder in a Prader-Willi syndrome patient", J Clin Psychiatry 48:423 (1987)). Carbamazepine has also been reported useful in the treatment of pathological gambling (Haller, R.; Hinterhuber, H., "Treatment of pathological gambling with carbamazepine", Pharmacopsychiatry 27:129 (1994)). There are also reports in the literature of divalproex being effective for explosive mood and mood lability (Donovan, S.J.; Stewart, J.W.; Nunes, E.V.; Quitkin, F.M.; Parides, M.; Daniel, W.; Susser, Klein D.F., "Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled crossover design", Am J Psychiatiy 157:818-820 (2000)) and for a patient with kleptomania and mixed mania (Kmetz, G.F.; McElroy, S.L.; Collin, D.J., "Response of kleptomania and mixed mania to valproate", Am J Psychiatry 154:580- 581 (1997)).
[0011] Prader-Willi Syndrome (PWS) is a neurogenetic multisystem disorder characterized by infantile hypotonia, mental retardation, short stature, hypogonadism, dysmorphic features, and hyperphagia with a high risk of obesity. Also very common in PWS are behavioral and psychiatric manifestations. These include self-injury (e.g. gouging, nail biting, and skin picking), explosive outbursts, oppositional behavior, obsessive ruminations, and compulsive behaviors including hoarding, counting, and arranging. PWS is typically a sporadic condition, which usually results from a deletion in chromosome 15ql l- ql3 or maternal uniparental disomy of chromosome 15. Glenn, C.G.; Driscoll, D.J.; Thomas, P.Y.; Nicholls, R.D., "Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes", MolHum Reprod 3:321-332 (1997).
[0012] PWS is also a relatively common genetic condition with an estimated prevalence of approximately 1/10,000 to 1/25,000. Glenn, C.G.; Driscoll, D.J.; Thomas, P.Y.; Nicholls, R.D., "Genomic imprinting: potential function and mechanisms revealed by the Prader-Willi and Angelman syndromes", Mol Hum Reprod 3:321-332 (1997). It was first described in 1956 (Prader, A.; Labhart, A.; Willi, H., "Ein Syndrome von adipositas, Kleinwuchs, Kryptorchismus und Oligophrenic nach myoteniertigem zusland in neugeborenanalter", Schwiez Med Wschr 86:1260-1 (1956)), and the physical problems (such as the obesity related cardiovascular diseases, diabetes mellitus, etc.) and behavioral problems result in the major causes of morbidity and mortality. Martin, A.; Matthew, S.; Koenig, K.; et al, "Prader-Willi syndrome", Am J Psychiatry 155:1265-1273 (1998). [0013] Treatment for the physical, behavioral, and psychological problems associated with PWS is complex. The mainstay of treatment for behavioral problems including hyperphagia is behavioral modification including strategies such as token economies or star systems. Dykens, E.M.; Hodapp, R.M., "Treatment issues in genetic mental retardation syndromes", Professional Psychology: Research and Practice 28:263-270 (1997). Additionally, medication management of individuals with PWS has been demonstrated to have benefit. Growth hormone therapy in children with PWS can increase muscle tone and enhance growth. Carrel, A.L.; Myers, S.C.; Whitman, B.N; et al., "Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study", J Pediatr 134:215-221 (1999); Lindgren, A.C.; Hagenas, L.; Muller, J.; et al, "Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report", The Swedish National Growth Hormone Advisory Group. Ada Paediatr Suppl 423:60-62 (1997). Therefore, growth hormone can help to normalize body habitus. Martin, A.; Matthew, S.; Koenig, K.; et al, "Prader-Willi syndrome", Am J Psychiatry 155:1265-1273 (1998); Carrel, A.L.; Myers, S.C.; Whitman, B.Y.; et al, "Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study", J Pediatr 134:215-221 (1999); Lindgren, A.C.; Hagenas, L.; Muller, j.; et al, "Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: a preliminary report", 77ze Swedish National Growth Hormone Advisory Group. Ada Paediatr Suppl 423:60-62 (1997). In terms of obesity, the anorectic fenfluramine was shown to be helpful for weight loss and aggressive behavior in PWS utilizing a double-blind placebo-controlled trial. Selikowitz, M.; Sunman, j.; Pendergast, A.; et al, "Fenfluramine in Prader-Willi syndrome: a double-blind, placebo controlled trial", Arch Dis Childhood 65:112-114 (1990). Unfortunately due to cardiovascular consequences, fenfluramine is not now currently available. There are few studies of anorectic agents in PWS and anecdotal reports have been discouraging in terms of their benefits. Martin, A.; Matthew, S.; Koenig, K.; et al, "Prader-Willi syndrome", Am J Psychiatry 155:1265-1273 (1998).
[0014] Pathological skin picking (PSP) is a severe and chronic psychiatric and dermatologic problem with an average age of onset around 15 years of age and mean duration of illness of 21 years. Keuthen, W.S.; Deckersbach, T.; Engelhard, I.M.; et al, "Self- injurious skin picking: clinical characteristics and comorbidity", J Clin Psychiatry 60:454- 459 (1999). PSP can lead to significant suffering, dysfunction, and disfigurement. Ko, S.M., "Under-diagnosed psychiatric syndrome II: Pathologic skin picking", Ann Acad Med Singapore 28:557-559 (1999). Furthermore, there is often psychiatric comorbidity. Keuthen, W.S.; Deckersbach, T.; Engelhard, I.M.; et al, "Self-injurious skin picking: clinical characteristics and comorbidity", J Clin Psychiatry 60:454-459 (1999). PSP is often considered an obsessive compulsive spectrum disorder (Goldsmith, T.D.; Shapira, N.A.; Phillips, K.A.; et al, "Obsessive Compulsive Spectrum Disorders"; in: Swinson, R.P.; Antony, M.M.; Rachman, S.; Richter, M.A. (Eds)., Obsessive-Compulsive Disorder: Theory, Research, and Treatment, Guilford Publications, New York, pp.397-425 (1998)) and, as such, there are several reports of serotonin receptor inhibitors (SSRI) medication being helpful. Ko, S.M., "Under-diagnosed psychiatric syndrome II: Pathologic skin picking", Ann Acad Med Singapore 28:557-559 (1999).
[0015] The literature points to topiramate having a negative impact on cognitive functioning including impaired concentration, attention, memory, slowed thinking, word finding, and verbal fluency. Thompson, P.J.; Baxendale, S.A.; Duncan, J.S.; et al; "Effects of topiramate on cognitive function", J Neurol Neurosurg Psychiatry 69:636-641 (2000); Privitera, M.; Fincham, R.; Penry, J.; et al, "Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages", Topiramate YE Study Group. Neurology 46:1678-1683 (1996); Crawford, P., "An audit of topiramate use in a general neurology clinic", Seizure 7:207-211 (1998); Jones, M.W., "Topiramate — safety and tolerability", Can J Neurol Sci 25:S13-15 (1998); Burton, L.A.; Harden, C, "Effect of topiramate on attention", Epilepsy Res 27:29-32 (1997); Martin, R.; Kuzniecky, R.; Ho, S. "Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults", Neurology 52:321 (1999); Fraught, E.; Wilder, B.J.; Ramsay, R.E.; et al, "Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600- mg daily dosages," Neurology 46:1684-1690 (1996); and Rosenfeld, W.E.; Liao, S.; Kramer, L.D.; et al, "Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy", Epilepsia 38:324-333 (1997). A few studies have systematically looked at cognitive changes using neuropsychological testing. In one study (Burton, L.A.; Harden, C, "Effect of topiramate on attention", Epilepsy Res 27:29-32 (1997)), 10 adult patients with epilepsy were evaluated weekly for up to 13 weeks via a digit span test. In 4 patients, there was an inverse correlation between topiramate does and test performance. In another study, healthy volunteers were treated with topiramate, gabapentin, or lamotrigine for 4 weeks. Impaired cognitive functioning (attention and word fluency) was seen in the topiramate treated subjects and not in gabapentin or lamotrigine in these healthy young adults. Martin, R; Kuzniecky, R.; Ho, S. "Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults", Neurology 52:321 (1999). Finally, in a recent study of 18 epilepsy patients treated with topiramate and receiving repeat neuropsychological assessments, patients on topiramate showed significant deterioration in many cognitive domains, including verbal IQ, verbal fluency, and verbal learning. Thompson, P.J.; Baxendale, S.A.; Duncan, J.S.; et al; "Effects of topiramate on cognitive function", J Neurol Neurosurg Psychiatry 69:636-641 (2000). Improvement in verbal fluency, verbal learning, and digit span increased in patients where topiramate was withdrawn or reduced.
[0016] The subject invention has, surprisingly, found improvements in impulsivity control, without negative effects on attention and concentration, in patients treated with topiramate. These observations are unexpected and novel.
Brief Summary of the Invention
[0017] The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the subject invention provides methods for treating or controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. In another embodiment, the subject invention provides for methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V. Compositions are administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V. Brief Description of the Drawings
[0018] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication, with color drawing(s), will be provided by the Office upon request and payment of the necessary fee.
[0019] Figures 1, 3, 5, and 7 depict the efficiency ratios of patients treated with topiramate as measured by the Delay Task of the Gordon Diagnostic.
[0020] Figures 2, 4, 6, and 8 depict the total correct responses of patients treated with topiramate as measured by the Vigilance Task of the Gordon Diagnostic.
[0021] Figures 9A-D and 10A-C depict the progression of wound healing in patients treated with topiramate.
[0022] Figures 11A-B: Photographs of improvement in wound healing for Ms. A on topiramate (75 mg/day) at week 4 (Figure 11 A) and 150 mg/day topiramate at week 8 (Figure 1 IB).
[0023] Figures 12A-B: Photographs of improvement for Mr. B. Mr. B. on 25 mg/day topiramate (Figure 12A), Week 1; Mr. B. on 200 mg/day topiramate (Figure 12B), Week 8.
[0024] Figures 13A-B: Photographs of primary SIB lesions. Ms. C. (right breast), baseline (Figure 13 A); Ms. C. on 175 mg/day (right breast), Week 8 (Figure 13B).
[0025] Figure 14: Number of ulcerated SIB lesions for Ms. C. as documented by group home staff utilizing systematic full body surveys (* denotes lesions smaller than previous lesions and appearing to result after insect bites).
[0026] Figures 15A-B: Photographic record of Ms. A hair loss at start of treatment (Figure 15 A) and during treatment (Figure 15B).
[0027] Figure 16 illustrates the reported reduction in the urge of Ms. A to pull hair.
[0028] Figure 17 represents the improvement in impulse control for Ms. A during treatment using the Gordon Diagnostic System. [0029] Figure 18 illustrates that Ms. A suffered no significant change in cognitive ability during treatment.
Detailed Disclosure of the Invention
[0030] The subject invention provides methods and compositions for the treatment of neurogenetic disorders, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, an individual is treated in methods comprising the administration of therapeutically effective amounts of compositions comprising compounds selected from the group consisting of formulas I-V. In one embodiment, therapeutically effective amounts of topiramate are administered to individuals topically or orally. In another embodiment, compositions comprising one or more of the compounds disclosed in fonnulas I-V are administered for the control or treatment neurogenetic disorders. In preferred embodiments the neurogenetic disorders include PWS and ADHD.
[0031] Thus, the subject invention provides methods and compositions for the treatment or control of ADHD or PWS. In one embodiment, the subject invention provides methods for controlling symptoms associated with ADHD or PWS comprising the administration of therapeutically effective amounts of compositions containing compounds of the formulas I-V. One embodiment of the invention provides therapeutically effective compositions comprising one or more of the compounds of formulas I-V and acceptable carriers.
[0032] In another embodiment, the subject invention provides methods of promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising the compounds of formulas I-V to an individual having a wound. In one embodiment, compositions are topically administered to a wound. The compositions may take the form of a salve, ointment, or aerosol applied to the site of injury. Alternatively, the compositions may be administered to the wound site as a component of a bandage or transdermal patch. In these instances, the compositions may be an integral component of the bandage or transdermal patch and are thereby applied to the wound site. In another embodiment, therapeutically effective amounts of the compounds comprising formulas I-V are incorporated into bioadhesive compositions useful in wound closure. In yet another embodiment, therapeutically effective amounts compositions comprising the compounds of formulas I-V are administered orally.
[0033] As the subject invention provides methods of promoting wound healing or controlling impulsive behavior in an individual, the subject invention provides methods having both human and veterinary utility. The term "individual" includes animals of avian, mammalian, or reptilian origin. Mammalian species which benefit from the disclosed methods include, and are not limited to, apes, chimpanzees, orangutans, humans, monkeys; domesticated animals (pets) such as dogs, cats, guinea pigs, hamsters, Vietnamese pot-bellied pigs, rabbits, and ferrets; domesticated farm animals such as cows, buffalo, bison, horses, donkey, swine, sheep, and goats; exotic animals typically found in zoos, such as bear, lions, tigers, panthers, elephants, hippopotamus, rhinoceros, giraffes, antelopes, sloth, gazelles, zebras, wildebeests, prairie dogs, koala bears, kangaroo, opossums, raccoons, pandas, giant pandas, hyena, seals, sea lions, and elephant seals. Reptiles include, and are not limited to, alligators, crocodiles, turtles, tortoises, snakes, iguanas, and/or other lizards. Avian species include, and are not limited to, chickens, turkeys, pigeons, quail, parrots, macaws, dove, Guinea hens, lovebirds, parakeets, flamingos, eagles, hawks, falcons, condor, ostriches, peacocks, ducks, and swans. Therefore, the subject invention provides methods of controlling the impulse of an individual to scratch, pick, lick, or otherwise cause self-injury by repeated mechanical irritation of an injured area.
[0034] Bandages and wound dressings incorporating materials to promote wound healing are well known in the art (see, for example, U.S. Patent Nos. 6,143,037 6,142,982
6,136,341; 6,132,759; 6,124,273 6,096,709 6,093,388 6,087,549; 6,051,249 6,033,684 6,025,150; 6,022,556; 5,998,692 5,989,577 5,981,606 5,977,428; RE36,370 5,972,332; 5,968,001; 5,960,795; 5,955,430 5,914,125 5,902,600 5,897,516; 5,876,743 5,874,479 5,863,938; 5,856,364; 5,856,245 5,834,432 5,807,341 5,807,300; 5,804,213 5,780,048 5,759,570; 5,735,812; 5,716,935 5,716,337 5,713,842: 5,707,647; 5,705,477 5,692,302; 5,685,834; 5,674,912; 5,667,501 5,663,208 5,662,924 5,662,904; 5,658,957 5,658,956 5,652,274; 5,648,380; 5,646,190 5,641,814 5,633,285 5,632,727; 5,629,292 5,614,561
5,610,148; 5,603,946; 5,602,183; 5,578,022; 5,571,521 5,525,335; 5,522,794 5,520,926:
5,519,020; 5,512,291; 5,512,041; 5,507,775; 5,578,310, each of which is incorporated by reference in its entirety). [0035] Bioadhesives incorporating materials to promote wound healing are well known in the art (see, for example, U.S. Patent Nos. 5,981,606; 5,874,479; 5,863,938; 5,856,364; 5,692,302; 5,674,912; 5,663,208; 5,658,957; 5,658,956; 5,652,274; 5,648,380; 5,646,190; 5,641,814; 5,633,285; 5,631,019; 5,614,561; 5,602,183; 5,578,310, each of which is incorporated by reference in its entirety).
[0036] Compounds of formulas I-V are anti-epileptic compounds, which are highly effective anti-convulsants. The compounds useful in the practice of the instant invention include the individual isomers, analogs, and homologs of the disclosed anti-convulsant compounds. Racemic mixtures, as well as the isolated enantiomeric forms, of the compounds can also be used in the practice of the subject invention.
[0037] In addition, the compounds useful for the practice of the subject invention include pharmaceutically acceptable salts, for example; alkali metal salts, such as sodium or potassium, ammonium salts, dialkyammonium salts, trialkylammonium salts, tetraalkylammonium salts, and tromethamine salts. Hydrates and other solvates of the compounds are also included within the scope of the compounds useful in the practice of this invention.
[0038] One such compound is taught and disclosed in U.S. Pat. No. 4,513,006, hereby incorporated by reference in its entirety. 2,3:4,5-bis-0-(l-methylethylidene)-β-D- fructopyranose sulfamate, known as topiramate, has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures. Other useful compounds include those described by formula I, including (tetrahydro-2H-pyran-2-yl)methane sulfamate, and 2,3:4,5-bis-0-(l-methylethylidene)-β-D-fructopyranose methylsulfamate
Figure imgf000012_0001
(Formula I)
wherein
Xi is CH2 or oxygen; Ri is hydrogen or alkyl; and
[0039] R2, R3, R , and R5 are independently hydrogen or lower alkyl and, when X] is CH2, R4, and R5 may be alkene groups joined to form a benzene ring and, when Xi is oxygen, R2 and R3 and/or * and R5 together may be a methylenedioxy group of the following formula:
R6 O —
\ /
C / \ R7 O —
wherein R6 and R are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
[0040] For compounds of formula I, R] may be hydrogen or an alkyl of about 1 to 4 carbons, such as methyl, ethyl, and isopropyl. Alkyl includes straight and branched chain alkyl. For compounds of formula I, Alkyl groups for R2, R3, R4, R5, R6, and R7 are of about 1 to 3 carbons and include methyl, ethyl, isopropyl and N-propyl.
[0041] When Xj is CH2, R and R5 may combine to form a benzene ring fused to the 6-membered X] -containing ring, i.e., j and R5 are defined by the alkatrienyl group -CH— CH=CH— CH=.
[0042] In one embodiment, Xi is oxygen and both R2 and R3 and 4 and R5 together are methylenedioxy groups of the formula wherein R6 and R7 are both hydrogen, both alkyl or combine to form a spiro cyclopentyl or cyclohexyl ring, in particularly where R6 and R7 are both alkyl such as methyl. In another embodiment, Xi is CH2 and 4 and R5 are joined to form a benzene ring. Another embodiment provides compounds of formula (I) wherein both R2 and R3 are hydrogen.
[0043] Other compounds (formulas II- VI) and compositions useful in the practice of the subject invention may be found in the teachings of U.S. Pat. Nos. 5,384,327, 5,498,629, 5,654,461, 5,892,088, and 6,071,537, each of which is incorporated by reference in their entireties. [0044] These compounds include those provided by the structure:
Figure imgf000014_0001
(Formula II)
wherein R6 and R7 may be the same or different and are selected from any of hydrogen or Ci to C4 alkyl. In one embodiment, R6 and R7 are each hydrogen.
[0045] R8 and R9 may be the same or different and are selected from any of hydrogen or Ci to C4 alkyl. In one embodiment, R and R9 are each Cj to C4 alkyl.
[0046] Rio and Ri i may be the same or different and are selected from any of azido, halogen, hydroxyl, sulfamoyl (H2NS020), Ci to C4 alkoxy, Ci to C alkyl thiocarbonate (RSC(O)O), Ci to C4 alkyl carbonate (ROC(O)O), or Ci to C4 alkyl carboxylate (RC(O)O), wherein R is Ci to C alkyl. In one embodiment, Rio and Rn are selected from any of CpC alkyl thiocarbonate, halogen or hydroxyl.
[0047] For compounds of formula II, the terms alkyl and alkoxy include straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, n- butyl, isobutyl, and t-butyl. Halogen includes bromine, chlorine, fluoride and iodine.
[0048] Preferred compounds of the formula (II) are those wherein the pyran ring is in the L-sorbopyranose absolute configuration. Particularly preferred compounds of formula (II) are those wherein the pyran ring is in the L-sorbopyranose absolute configuration, R6 and R are each hydrogen, R8 and R9 are each methyl; Rio is methyl thiocarbonate (CH3SC(0)0) and Rn is halogen; or Rio and Rn are both halogen; or Rio is hydroxyl and Rn is halogen. Particularly preferred halogens include bromine, chlorine, and iodine.
[0049] Specific examples of compounds of formula (II) are: (1) 5-deoxy-5-iodo- 2,3-0-(l-methylethylidene)-4-[methylthiocarbonyl)]-α-L-sorbopyranose sulfamate, (i.e., where the compound is in the L-sorbopyranose absolute configuration, Re and R7 are hydrogen, R8 and R9 are methyl, Rio is CH3SC(0)0, and Rn is iodine); (2) 4,5-dibromo-4,5- dideoxy-2,3-0-(l-methylethylidene)-α-L-sorbopyranose sulfamate, (i.e., where the compound is in the L-sorbopyranose absolute configuration, R6 and R7 are hydrogen, R8 and R9 are ' methyl, Rι0 and Rn are bromine); and (3) 5-chloro-5-deoxy-2,3-0-(l- methylethylidene)-α-L-sorbopyranose sulfamate, (i.e., where the compound is in the L- sorbopyranose absolute configuration, Rβ and R7 are hydrogen, R8 and R9 are methyl, Rio is hydroxyl, and Rn is chlorine).
[0050] Another compound useful in the practice of the invention is described in Formula III:
Figure imgf000015_0001
(Formula III)
wherein Rι2 and Rι3 are the same or different and are selected from any of hydrogen, alkyl ( to C6), cycloalkyl (C3-C7), allyl, or benzyl. In one embodiment, Rι2 and Rn are each hydrogen. Rι4 and R15 are the same or different and selected from hydrogen or lower alkyl.
[0051] X2 may be chosen from carbon (C) or sulfur (S), with the stipulation that when X2 is carbon, Rι6 and Rι7 are the same or different and are selected from hydrogen or lower alkyl, whereas when X2 is sulfur one of Rι6 and R]7 is oxygen and the other is a lone pair of electrons or both Rι6 and Rn are oxygen.
[0052] For compounds of formula III, the term alkyl includes straight and branched chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, and t-butyl.
[0053] Particularly preferred compounds of formula III are: (1) (1R,2R,3S,4S)- (l,2:3,4-di-0-methylethylidenecyclohexan-l,2,3,4-tetraol-r-yl)methyl sulfamate, (i.e., where R]2 and Rι3 are hydrogen, Rι4, R15, Rι6, and Rι7 are methyl and X2 is carbon); (2) ( 1 R,2S,3 S,4S)-(3 ,4-O-methylethylidene- 1 ,2-O-sulfonyl-cyclohexan- 1 ,2,3,4-tetraol-4-yl) methyl sulfamate, (i.e., where Ri2 and Rι3 are hydrogen, R!4 and R]5 are methyl, Rι6 is oxygen and R]7 is an electron pair and X2 is sulfur); and (3) (lR,2S,3S,4S)-(3,4-0- methylethylidene- l,2-0-sulfonyl-cyclohexan-l,2,3,4-tetraol-4-yl)methyl sulfamate, (i.e., where R]2 and R]3 are hydrogen, R)4 and R]5 are methyl, Rι6 and R]7 are both oxygen and X2 is sulfur).
[0054] Another compound useful in the subject invention is
Figure imgf000016_0001
(Formula rv)
[0055] Other compounds useful in the practice of the invention include those of Formula V
Figure imgf000016_0002
(Formula V)
wherein, AR is represented by the following formulas:
Figure imgf000016_0003
[0056] Y is selected from the group consisting of halogens such as F, Cl, Br and I, or trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; when X3, which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms. Rι8, Rι , R20, and R21, may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NRι8Rι and NR2oR2ι, identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom. [0057] Compositions useful in the practice of this invention comprise one or more of the compounds of formulas I-V admixed with a pharmaceutical carrier. The compositions may be made according to conventional pharmaceutical compounding techniques. Thus, the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., injection, oral, suppository, topical, or parenteral.
[0058] In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
[0059] Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. Suppositories may be prepared, in which case cocoa butter could be used as the carrier.
[0060] For parenterals, the carrier will usually comprise sterile water, though other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
[0061] Other compositions useful in the practice of the subject invention include salves, cosmetics, ointments, and the like. Such compositions may be topically applied to a site or incorporated into articles of manufacture including, but not limited to, bandages, adhesive strips for the covering of wounds (e.g., BAND AID brand adhesive strips), or transdermal patches. Carriers such as cocoa butter, viscous polyethylene glycols, hydrogenated oils, and such mixtures can be emulsified if desired.
[0062] Compounds of the subject invention may also be incorporated into cosmetics. Additional materials and substances suitable as carriers for the compounds of formulas I-V are described in the International Cosmetic Ingredient Dictionary and Handbook, 8th Edition (The Cosmetic, Toiletry, and Fragrance Association (CTFA), 2000), hereby incorporated by reference in its entirety.
[0063] Where the pharmaceutical compositions are aerosols, the active ingredients can be packaged in pressurized aerosol containers with a propellant, e.g., carbon dioxide, nitrogen, propane, etc. with the usual adjuvants such as cosolvents, wetting agents, etc.
[0064] In accordance with the invention, pharmaceutical compositions comprise, as an inactive ingredient, an effective amount of one or more non-toxic, pharmaceutically acceptable ingredient(s). Examples of such ingredients for use in the compositions include ethanol, dimethyl sulfoxide, glycerol, silica, alumina, starch, calcium carbonate, talc, flour, and equivalent non-toxic carriers and diluents.
[0065] The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder injection, teaspoonful, suppository, bandage, and the like, from about 0.1 to about 400 mg of the active ingredient. In a preferred embodiment, the compositions comprise about lOmg to 200 mg per dosage unit. In an even more preferred embodiment, the compositions contain comprise about 20mg to about lOOmg of active ingredient. In another embodiment, the compositions comprise about 25mg of active ingredient per unit dose.
[0066] Topiramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent. The tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methyl cellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.
[0067] It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims. All publications and patents cited herein are hereby incorporated by reference in their entireties. Example 1- Effects of topiramate on impulsivity and cognitive functioning
[0068] There are no reports of topiramate being utilized in PWS for any behavior. Measurements of attention, concentration, and impulsivity were assessed by the Delay and Vigilance tasks of the Gordon Diagnostic System (GDS; Gordon, M.; McClure, F.D.; & Aylward, G.P. (1996) Gordon Diagnostic System, Interpretive Guide (Third Edition); Dewitt, N.Y.: Gordon Systems, Inc.), a mechanized evaluator of cognitive functions, including attention and concentration. The GDS was originally developed, and most commonly used, to measure aspects of Attention-Deficit/Hyperactivity Disorder (ADHD) (previously called Attention-Deficit Disorder). One of the important components of the Vigilance test is the ability of an individual to have sustained attention, and the Delay task in part measures the subjects' ability to concentrate and focus on hitting a button at appropriate time intervals and delay impulsive behavioral responses.
[0069] The Delay Task requires that the subject inhibit responding (pressing a button and then refraining from pressing the button again for at least 6 seconds) in order to earn points. The Delay Task measures the subject's ability to suppress and delay impulsive behavioral responses. While focusing and sustaining attention usually facilitate Delay Task performance, the Delay Task maximally draws on a subject's ability to inhibit impulsive responses. The Delay Task's total efficiency ratio (EF) is considered the best indicator (score ranges from 0 to 1) of the level of impulsivity with the lower the score (such as less than .5) indicating higher impulsivity and poor self-control. The Vigilance Task measures the subject's ability to focus attention on a task and to maintain this attention over a period of time without reinforcement. The correct responses (CR) of the Vigilance Task measures the level of alertness and is a measure of the subjects attentional processes.
[0070] JAS-002 (patient Number 2) had a baseline total efficiency ratio (ER) of 0.02, approximately 8 standard deviations below the normal range and well below the first percentile in regards to the Delay task. This falls markedly within the range of an "abnormal" performance as stated in the rating score manual provided by the manufacturer of the GDS. At visit 4, approximately 1 month after starting medication (at a dose of 100 mg/day), JAS-002 demonstrated dramatic improvement in ER (a value of 0.98), well within the normal range of performance. At 2 months (at a dose of 175 mg/day), JAS-002 continued with improvements in ER (a value of 0.85), within the normal range of performance. Attention as evaluated by the Vigilance Task for JAS-002 showed essentially no change for CR from 39 at baseline to 38 (at a dose of 175 mg/day) at 2 months.
[0071] For patient Number 1 (MJG-001), a significant improvement has been noted. At baseline, MJG-001's ER for the Delay Task was at a value of 0.06 (approximately 7 standard deviations below the average ER) demonstrating a severe impairment of impulsivity. However, at the second testing session, MJG-001 showed moderate improvement with a Delay Task ER of 0.24. At visit 5, approximately 1.5 months after starting medication (at a dose of 75 mg/day), MJG-001 demonstrated a substantial improvement with an ER value of 0.46 and two weeks later (at a dose of 125 mg/day) had an ER value of 0.70. At 2 months after starting medication (at a dose of 150 mg/day), MJG-001 demonstrated a substantial improvement with an ER value of 0.50. The Vigilance Task for MJG-001 showed some variability up and down during the study and, after approximately 2 months, showed a mild decrease of CR from 43 to 41 (at a dose of 150 mg/day).
[0072] Patient Number 3 (GFV-003) has also shown a severe deficit in impulsivity and focusing; baseline ER was 0.02 (a value 8 standard deviations below the normal range). At visit 1 , after one week at a low dose of topiramate (25 mg/day), GFV-003 had improved to an 0.09 ER and by week 4 (at a dose of 100 mg/day) to an ER of 0.19, and by 2 months (at a dose of 200 mg/day) the ER was at 0.10. The Vigilance Task for GFV-003 showed variability on topiramate and by the end of two months was essentially unchanged with a CR decreasing from 16 at baseline to 15 at 2 months.
[0073] Patient #4 (MCK-004) also showed abnormal performance on the Delay task (ER of 0.35). Within 1 week on low dose topiramate (25 mg/day) MCK-004 had improved to an ER of 0.51, by the 2nd week on 50 mg/day topiramate, the ER was 0.76, and continued improvement by the 3rd week on 75 mg/day with an ER of 0.65 and by two months at a dose of 150 mg/day, her ER continued to be improved at 0.64. The Vigilance Task for MCK-004 shows mild decrease from baseline CR of 38 to 34 (by the 8th week on 150 mg/day).
[0074] Thus, the use of topiramate for impulsivity, without negative effects on attention and concentration, is both novel and clinically applicable. Disorders with impulsivity and deficits in attention and concentration are difficult to manage for both the patient and their caregiver, especially in cases of dementia. Impulsivity and lack of concentration can severely handicap day-to-day functioning in all age groups affected by these disorders. There are no reports in the literature of topiramate specifically used to treat impulsivity and/or deficits in attention and concentration.
Example 2- Effect of topiramate on pathologic skin picking (PSP)
[0075] There are no reports of topiramate being utilized in PWS for any behavior. Patient #3 (GFV-003) also has pathologic skin picking (PSP) in addition to food seeking behavior. Patient #3 has a chronic large lesion on his lower left arm. Within one week of topiramate (25 mg/day), he had decreased skin picking and showed healing of this lesion on his left arm. By the 4th week on topiramate (at 100 mg/day), the lesion on his lower left arm had completely healed over. The progression of wound healing is provided in Figures 9A-D and 12A-B.
[0076] Patient #1 (MJG-001) has pathologic skin picking (PSP) in addition to food seeking behavior. Unexpectedly and serendipitously, it was observed that several large lesions (where she skin picks) on her right arm, legs, and lips were clearing up quickly (within 5 days) after topiramate was initiated at 25 mg/day. Furthermore, the patient has continued to do well in terms of skin clearing. For example, a large lesion on her right arm completely healed over after about 2 months on topiramate (at a dose of 125 mg/day). The patient lives in a group home and workers there, as well as her mother, have also commented to us that her skin picking/skin has overall improved. The progression of wound healing is provided in Figures 10A-C and 11A-B.
[0077] The use of topiramate for PSP and related disorders is also novel and clinically applicable. There are no FDA approved pharmacological treatments for pathologic skin picking (also referred to as neurotic excoriation, repetitive skin picking, compulsive skin picking, and dermatotillomania) and possible related obsessive-compulsive spectrum disorders (t.e., repetitive self-mutilation (RSM), oncophagia, rhinotillxomania, trichotillomania) (Goldsmith, T.D.; Shapira, N.A.; Phillips, K.A.; et al, "Obsessive compulsive spectrum disorders"; im Swinson, R.P.; Antony, M.M.; Rachman, S.; Richter, M.A. (Eds)., Obsessive-Compulsive Disorder: Theory, Research, and Treatment, Guilford Publications, New York, pp.397-425 (1998)). Example 3 - Effects of Topiramate on patients with Prader-Willi Syndrome
[0078] In an 8-week, open-label, flexible-dose (maximum 350mg/day) study to evaluate the efficacy and safety of topiramate in PWS adults, weekly evaluations were performed that included scales for stereotypical behavior (Stereotypy Checklist, Y-BOCS checklist), aberrant behavior (Aberrant Behavior Scale {ABS}, Severity of Symptoms Scale, Self-Injury and Self-Restraint Checklist) and cognitive functioning (Gordon Diagnostic, Controlled Oral Word Association Test, Semantic Naming test). Subject safety measures were also performed (e.g., monitoring blood pressure). Appetite was assessed for one hour at four time points during the trial. Measurements were made by investigator observation of the subject with free access to low calorie food and a visual analogue scale before and after observation.
[0079] Eight subjects (19-36 years of age; 4 males and 4 females) entered the trial and six have completed the treatment regimen. A mean weight loss of 0.3 pounds was observed over the course of the study. Appetite tests show a mean increase of 255.8 calories/hour; however, a dramatic reduction in self-injurious behavior was also observed (e.g., skin picking). Five subjects have continued long-term on topiramate for at least 6 months (mean of 8.2 + 1.5 months) and, in these subjects, there has been mean 4.9 lb + 4.0 lb weight loss. Behavior evaluations have shown a reduction in aberrant behaviors (such as irritability and noncompliance [Mean ABS at baseline of 8.5 + 7.2 and mean ABS at week 8 of 5.3 + 5.1, *Z= -2.0, df=l, P= .042 {Wilcoxon signed-ranks test}]) and self-injury in all four subjects exhibiting these behaviors. Healing of skin lesions was also observed. Open- label administration of topiramate has been shown to improve behavior and decrease self- injury in PWS subjects. Longer treatment lengths appear to result in steady weight decrease.
Example 4 - Effects of Topiramate on Prader-Willi Syndrome
[0080] In the above study was performed to assess the effects of topiramate on PWS. All subjects provided written informed consent for topiramate treatment and were between 18 and 65 years of age. Criteria for exclusion included: clinically significant suicidality or homicidality; current or recent (within 6 months of the start of topiramate) DSM-IV diagnosis of substance abuse or dependence; a clinically unstable disease that could interfere with treatment or assessment of PWS; treatment with any drug that might interact adversely with topiramate; and personal or family history of nephrolithiasis. Women of childbearing potential who were not taking adequate contraceptive measures were not included. Screening measures included a physical examination, psychiatric background, medication history, blood draw for laboratory assessment (CBC, SMA-12, urinalysis, and a B-hCG for women of childbearing potential), and the Structured Clinical Interview for DSM- IV, Patient Edition (SCID-P). Weekly assessments of weight loss, participant functioning, and safety measures including blood pressure and pulse were taken by the investigators at each visit. Participants are residents of group homes operated by the Association of Retarded Citizens, Alachua County, Florida (ARC). These homes are monitored, thereby allowing recording of participants' behavioral and psychiatric manifestations as well as their medication management. Participants began pharmacotherapy with topiramate at 25 mg of drug given in the evening for 7 days. After 14 days, their daily dose could be increased in increments of up to 50 mg/week for the next 6 weeks.
[0081] Case 1: Ms. A. is a 19 year-old female who through DNA methylation testing was positive for PWS and shown to have a chromosomal deletion through FISH and DNA polymorphism analyses. Ms. A. has a history of hoarding and severe skin picking dating to childhood. Current concomitant psychiatric medications include fiuoxetine 60 mg/day and naltrexone 50 mg/day. Psychiatric intervention dated back to 1992 when the subject began therapy with clomipramine and fenfluramine, both of which were unsuccessful in managing her behavior and weight problem.
[0082] Initial side effects (of topiramate) experienced included mild sedation, word-finding difficulties, and unrelated lower back pain that resolved by Week 8. Ms. A's weight remained stable with a baseline of 129.51bs and weight of 128.51bs at Week 8. Ms. A had a long-standing primary lesion on her right forearm that measured approximately 4cm by lcm and ulcerated at baseline. She experienced a reduction in skin picking with improvement to the lesions on her face, arm, and legs noted by Week 4 (75mg/day). To better follow the improvement in her skin, a photographic record of Ms. A's lesion on her forearm was begun demonstrating healing of this lesion by Week 8 of topiramate (150 mg/day). See Figures 10A-C and 11A-B.
[0083] Case 2: Mr. B. is a 29 year-old male confirmed to be a chromosomal deletion as described above. He has a history of severe food seeking and skin picking dating to childhood. Mr. B does not have a history of taking psychotropic medications and had declined a previous recommendation to take fiuoxetine. Initial healing of his primary lesion (a round 1.5cm diameter ulcerated lesion) was noted within one week of initiating topiramate freatment (25mg/day) at which point photographic records were started. Mr. B also experienced some increased irritability when topiramate was initiated. Irritability returned towards baseline by Week 8. Mr. B also experienced a decrease in his weight from 180.0 lbs at baseline to 176.8 lbs at Week 8. By Week 8 of topiramate (200mg/day), Mr. B. had experienced remission of his self-injurious behavior (SIB) with resultant healing and complete unulceration of his primary lesion (Figures 9A-D and 12A-B).
[0084] Case 3: Ms. C. is a 32 year-old female confirmed to be a chromosomal deletion. Concomitant psychotropic medications include fiuoxetine 20mg/day. She has a history of food seeking and skin picking dating to childhood. Due to her employment, Ms. C. picks in multiple concealed locations (e.g., her chest, breasts, and the top of her legs). Because of her secrecy regarding SIB, the staff members of her group home daily perform full body surveys. As a result of previous experience with Ms. A and Mr. B, photographic records of her lesions were started prior to initiation of topiramate (Figure 13).
[0085] After beginning topiramate, an attenuation of SIB behavior and number of ulcerated lesions (Figure 14) was noted within 1 week (25 mg/day) by photographs and by 2 weeks (50 mg/day) by her group home staff. Side effects included word-finding difficulty, mild confusion, sedation, and some mild tingling in her left heel. All side effects resolved by Week 5. On topiramate, Ms. C experienced an increased weight from 1501bs at baseline to 154.51bs at Week 8. At Week 8, Ms. C. had continued attenuation of skin picking on a dose of 175mg/day (Figures 14 and 15). During participation, Ms. C. experienced a period of three weeks where she was without any SIB. However, reportedly as result of her picking at several insect bites, small ulcerated lesions appeared on her forearm and lower legs in Weeks 7 and 8.
[0086] These three cases further illustrate the beneficial effects of the anti-epileptic drug topiramate. Topiramate is able to attenuate self-injurious behavior in a patient population where SIB is common and difficult to manage and treat. All three subjects have longstanding histories of self-injury, and two subjects (Ms. A. and C.) had failed previous psychotropic medication interventions. Furthermore, all three PWS subjects have chosen to continue on topiramate after the 8-week trial (8 months for Ms. A., 7 months for Mr. B., and 4 months for Ms. C.) with continued improvement in self-injury. Improvement in self-injury was noted by both investigators and in systematic body evaluations by the group home in one subject (Ms. C). Additionally, while individuals with PWS often pick surreptitiously and pick even when they describe having no urges, all three subjects reported decreased urges to pick while on topiramate.
[0087] In terms of an objective measurement of impulsivity, subjects were also followed by the Delay Task of the computerized Gordon Diagnostic System (Gordon et al, 1996). The Delay Task measures a subject's ability to suppress and delay impulsive behavioral responses (Gordon et al, 1996). All three subjects demonstrated improvement in the Delay Task while on topiramate.
Example 5 - Effects of Topiramate on Impulsive Disorders in Mammals
[0088] Canine acral lick dermatitis (ALD), also known as lick granuloma, acral pruritic nodule, and neurodermatitis, is a common self-inflicted skin disorder in dogs in which localized alopecia and epidermal hyperplasia and fibrosis are caused by continued licking, biting, and/or scratching one or more areas usually near the carpus or hock. When severe, the licking of the paws or flank causes significant local trauma and, in extreme cases, may require surgery and steroids. Occasionally, the animal must be put to death because of chronic ulceration or osteomyelitis. The etiology of ALD is unknown, although, commonly, it is considered to be psychogenic in origin secondary to boredom, loneliness, or confinement. It can also be provoked by local irritation. Certain large breeds appear to be more susceptible, such as German Shepherds, Labrador Retrievers, and Great Danes. The repetitive self-licking, chewing, or scratching creates areas of hair loss and the production of lesions which may range in size from several centimeters to the entire surface of the limb. This stereotypic behavior prevents the lesions from healing and may cause discomfort, pain and, in severe cases, may prove crippling.
[0089] Twenty dogs will be recruited from the Veterinary Animal Teaching Hospital. Other causes of licking will be ruled out by examining the dogs' clinical history, typical lesion appearance, and past history of treatment response. Dogs must exhibit chronic licking of 6 months or more that has caused an observable lesion(s). Reasons for exclusion from the study include: dogs undergoing concurrent treatment for ALD, dogs weighing <5 kg, dogs that have not been neutered or spayed, nephrolithiasis, and a significant acute or chronic confounding disease. Once the referring veterinarian has consented to the dogs' involvement, letters inviting participation in the study will be sent out to the owners of appropriate candidates. An informed consent documents will also be obtained.
[0090] A double-blind placebo-controlled trial of 8 weeks duration (6 week treatment and 2 week taper) will be conducted. One-half of the dogs receive placebo. The dogs will start at 2 mg/kg in a split dose (1 mg/kg twice a day) for the first two weeks. The dose will be increased 2 mg/kg a week as tolerated for the next four weeks. Thus, the maximum dosage will not exceed 10 mg/kg. This dosage strategy is based upon the target dose for seizures, which is 5 to 10 mg/kg in split doses.
[0091] Topiramate or placebo will be administered via gelatin capsules once daily (5 minutes before feeding). Owners will be instructed to avoid feeding dogs anything in addition to their regular diet. In addition to adhering to the dogs' routine (e.g., food, exercise, and training), owners will also be asked to maintain environmental conditions for the duration of the study.
[0092] A video camera will record the dogs' behavior for 1 hour each week for the 6 weeks of the trial. The primary behavior of interest is self-licking or self-chewing of the granulomatous lesion. The measure of time the dogs are involved in licking or chewing will be computerized. The evaluator will press the designated key when the dog's tongue or lips first makes contact with the lesion, and at the end of a continuous bout of licking or chewing when the dog lifts its head from the lesion and transfers its attention elsewhere.
[0093] In addition to videotaping, the owners will rate their dogs' licking behavior on a 10-point scale, with 10 being the worst ever observed and 0 indicating a complete absence of excess licking (Acral Lick Dermatitis Severity Scale). Investigators will also rate the dogs' behavior using a similar scale. Finally, photographs of the lesions will be taken weekly. Additionally, at baseline, a checklist for phobias will be done with the owners and the list will be reviewed each week using clinical global impression scales to rate phobias.
[0094] A 2-week taper period will follow the 6-week treatment period. During week 7, study medication will be reduced by approximately 25% for 3 days. On day 4, the dosage will be reduced by another 25%. On day 11 the remaining dose will be reduced in half again and on day 13 all study medication will be stopped. The dogs' last visit will be day 14 of the taper period.
[0095] For each of the efficacy measures, a listing of each patient's score at each study week during treatment will be generated. The evaluation of change in efficacy measurements will be carried out using standard analysis of variance techniques. All statistical tests will be two-sided if not otherwise specified. A test will be said to be significant if p<0.05. Analyses will be preformed using the "intent-to-treat" population consisting of all dogs randomized into the trial who take at least one capsule of study medication and had at least one post-baseline evaluation. The primary efficacy variable will be the number of self-injurious behaviors observed by video camera during weekly visits. A dog's self injury duration (in min hr) is measured at the baseline and six weeks after treatment. The improvement score is the percentage of reduction (in ratio), i.e., improvement = (baseline - posttreatment)/baseline.
Example 6- Effects of topiramate on trichotillomania
[0096] Topiramate was used as an adjunct therapy in a 38 year-old female with a 9- year history of trichotillomania. She was on a stable dose combination of fluvoxamine and clomipramine. While the fluvoxamine/clomipramine combination was therapeutic for 3 years, 6 months ago Ms. A experienced an increase in hair pulling predominately on the left side of her head. The investigators have made photographic records of Ms. A.'s hair loss (Figures 15A-B) and she has been evaluated psychometrically for impulse control. Ms. A was started on a 25mg dose of topiramate at night and was gradually titrated in increments of 25mg to 150mg at night. Preliminary results suggest the addition of topiramate to this combination therapy effective for trichotillomania.
[0097] Before topiramate was initiated, clomipramine blood levels were as follows: clomipramine = 354 ng/ml, DM clomipramine = 118ng/ml, and clomipramine + DM clomipramine = 472 ng/ml. Following the addition of topiramate Ms. A reported a lessening of the urges to pull her hair starting at a relatively low dose (approximately 50mg/ day). Ms. A reported a significant reduction in the urge to pull by 3 weeks following the addition of topiramate and this improvement has been maintained for 14 weeks (Figure 16). Although patient described decreased urges to pull hair, her re-growth was minimal. Subsequent laboratory assessments when patient was on 150 mg of topiramate, 100 mg of clomipramine and 50 mg of fluvoxamine showed that although the ratio of parent to metabolite were the same as before topiramate (.69), both measurements were elevated: clomipramine = 514 ng/ml, DM clomipramine 181 ng/ml, clomipramine + DM clomipramine = 695 ng/ml.
[0098] After initial success with topiramate augmentation, the patient is currently being weaned off clomipramine and is currently on 25mg/day from lOOmg/day without any increase in urges to hair pull. Ms. A has experienced weight loss of approximately 5 lbs which she reports as a positive side effect. Possible other side effects of topiramate administration include disruption of attention and concentration and cognitive deficits such as word finding difficulties.
[0099] Ms. A has been evaluated psychometrically for these side effects. Results from the Delay task of the Gordon Diagnostic System, a widely used measurement of impulse control, have shown improvements from baseline (Figure 17). Subsequent testing of word finding abilities through the Control Oral Word Association Test (COW AT) and Semantic Category Naming test have shown no significant changes from baseline (Figure 18).
[00100] The patient has continued to see a reduction in the urge to, as well as in the time spent, pull her hair. Re-growth of hair at the sites previously pulled has also been observed. The patient is currently on 475 mg topiramate (p.o. q.h.s.).
Example 7 — Effects of Topiramate on Trichotillomania
[0100] A 19 year old female with a history of trichotillomania and skin picking has also been treated in accordance with the invention. She presented with skin lesions on her hands and face that resulted from picking at pimples (face) and pulling of hair on the backs of her hands. Several medications, in various classes, were previously tried without improvement (including mirtazapine, citalopram, gabapentin, paroxetine, nefazadone, and sertaline). The initiation of topiramate has resulted in the resolution of her trichotillomania, with noticeable re-growth of hair on the backs of her hands at 200 mg. p.o. q.h.s.) and has also resulted in improvements in the facial skin lesions. She is currently on 300 mg q.d. topiramate monotherapy.

Claims

Claims What is claimed is:
1. A method for treating or controlling neurogenetic disorders in an individual comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a pharmaceutically acceptable carrier.
2. The method according to claim 1, wherein said neurogenetic disorder is compulsive buying, problematic Internet use, or an impulse control disorder selected from the group consisting of intermittent explosive disorder, kleptomania, pyromania, pathologic gambling, and trichotillomania.
3. The method according to claim 1, wherein said neurogenetic disorder is Prader-Willi Syndrome.
4. The method according to claim 1, wherein said neurogenetic disorder is attention deficit hyperactivity disorder.
5. The method according to claim 1, wherein said anti-convulsant agent is selected from the group consisting of:
Figure imgf000029_0001
(Formula I)
wherein
Xi is CH or oxygen;
Ri is hydrogen or alkyl; and
R2, R3, t, and R5 are independently hydrogen or lower alkyl and, R2 and R3 and/or R and R5 together may be a methylenedioxy group of the following formula: R6 O —
\ / C
/ \ R7 O —
wherein R6 and R7 are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring,
Figure imgf000030_0001
(Formula II)
wherein R6 and R7 may be the same or different and are hydrogen or to C4 alkyl;
wherein R8 and R may be the same or different and are hydrogen or C\ to C4 alkyl;
wherein Rio and Rn may be the same or different and are azido, halogen, hydroxyl, sulfamoyl (H2NS020), d to C4 alkoxy, Ci to C4 alkyl thiocarbonate (RSC(O)O), Ci to C4 alkyl carbonate (ROC(O)O), or Cj to C alkyl carboxylate (RC(O)O), wherein R is Ci to C4 alkyl,
Figure imgf000030_0002
(Formula III)
wherein Rι2 and Rι3 may be the same or different and are hydrogen, alkyl (Ci to C6), cycloalkyl (C3-C7), allyl, or benzyl;
Rι and R15 are the same or different and selected from hydrogen or lower alkyl; and X2 may be chosen from carbon (C) or sulfur (S), with the stipulation that when X2 is carbon, Riβ and Rn are the same or different and are selected from hydrogen or lower alkyl, whereas when X2 is sulfur one of Riό and Rj is oxygen and the other is a lone pair of electrons or both R]6 and Ri7 are oxygen,
Figure imgf000031_0001
(Formula IV), and
Figure imgf000031_0002
(Formula V)
wherein, AR is represented by the following formulas;
Figure imgf000031_0003
Y is selected from the group consisting of halogens, trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; or
when X3, which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms; and
Ris, Rι9, R2o, and R2ι, may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NRι8R]9 and NR20R2ι, which may be identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom.
6. A method for promoting wound healing comprising the administration of a therapeutically effective amount of a composition comprising an anti-convulsant agent and a carrier.
7. The method according to claim 6, wherein said anti-convulsant agent is selected from the group consisting of:
Figure imgf000032_0001
(Formula I)
wherein
Xi is CH or oxygen;
Ri is hydrogen or alkyl; and
R2, R3, i, and R5 are independently hydrogen or lower alkyl and, R2 and R and/or R4 and R5 together may be a methylenedioxy group of the following formula:
Re O —
\ /
C / \ R7 O —
wherein R6 and R are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring,
Figure imgf000032_0002
(Formula II)
wherein R6 and R7 may be the same or different and are hydrogen or Ci to C4 alkyl; wherein R8 and R9 may be the same or different and are hydrogen or Ci to C4 alkyl;
wherein Rio and Rn may be the same or different and are azido, halogen, hydroxyl, sulfamoyl (H2NS020), Ci to C4 alkoxy, Ci to C4 alkyl thiocarbonate (RSC(O)O), Ci to C4 alkyl carbonate (ROC(O)O), or d to C4 alkyl carboxylate (RC(O)O), wherein R is Ci to C4 alkyl,
Figure imgf000033_0001
(Formula III)
wherein Rι2 and Rι3 may be the same or different and are hydrogen, alkyl (Ci to C6), cycloalkyl (C3-C7), allyl, or benzyl;
Rι and R15 are the same or different and selected from hydrogen or lower alkyl; and
X2 may be chosen from carbon (C) or sulfur (S), with the stipulation that when X2 is carbon, Rι6 and Rn are the same or different and are selected from hydrogen or lower alkyl, whereas when X2 is sulfur one of Rι6 and Rn is oxygen and the other is a lone pair of electrons or both Rι6 and Rj7 are oxygen,
Figure imgf000033_0002
(Formula IV)j and
Figure imgf000033_0003
(Formula V)
wherein, AR is represented by the following formulas;
Figure imgf000034_0001
Y is selected from the group consisting of halogens, trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms when Y alone is attached to the benzene ring; or
when X3, which may be S or O, is present, Y is selected from the group consisting of trifluoromethyl and alkyl groups containing 1 to 3 carbon atoms; and
Ris, R19, R20, and R21, may be identical or different and are selected from the group consisting of hydrogen, linear or branched alkyl groups containing 1 to 16 carbon atoms, cyclic alkyl groups containing 3 to 16 carbon atoms and aryl groups containing 6 to 8 carbon atoms, and NR]8Rι9 and NR20R21, which may be identical or different, each may form a 3 to 7-membered aliphatic cyclic compound together with another nitrogen atom or oxygen atom.
8. The method according to claim 6, wherein said composition comprises a salve, ointment, aerosol, cosmetic, or bioadhesive.
9. The method according to claim 6, wherein said composition is administered as a component of a bandage, transdermal patch, wound dressing, cosmetic, or bioadhesive.
10. The method according to claim 8, wherein said composition is a component of a bandage, wound covering, or wound dressing.
11. The method according to claim 1, wherein the therapeutically effective amount is about 0.1 to 400 mg.
12. The method according to claim 1, wherein the therapeutically effective amount is about 10 to 200 mg.
13. The method according to claim 1, wherein the therapeutically effective amount is about 25 mg.
14. The method according to claim 5, wherein the therapeutically effective amount is about 0.1 to 400 mg.
15. The method according to claim 5, wherein the therapeutically effective amount is about 10 to 200 mg.
16. The method according to claim 5, wherein the therapeutically effective amount is about 25 mg.
17. The method according to claim 1, wherein said neurogenic disorder is pathological skin picking and related disorders.
18. The method according to claim 1, wherein said neurological disorders are self- injury, gouging, nail biting, explosive outbursts, oppositional behavior, or obsessive ruminations.
PCT/US2001/044923 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing WO2002043731A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP01996012A EP1345602B1 (en) 2000-11-30 2001-11-30 Wound healing
AU2002227052A AU2002227052A1 (en) 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
CA002430010A CA2430010A1 (en) 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
DE60142632T DE60142632D1 (en) 2000-11-30 2001-11-30 HEALING OF WOUNDS
AT01996012T ATE474572T1 (en) 2000-11-30 2001-11-30 HEALING OF WOUNDS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25011300P 2000-11-30 2000-11-30
US60/250,113 2000-11-30

Publications (3)

Publication Number Publication Date
WO2002043731A2 true WO2002043731A2 (en) 2002-06-06
WO2002043731A3 WO2002043731A3 (en) 2003-02-20
WO2002043731B1 WO2002043731B1 (en) 2003-04-03

Family

ID=22946345

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044923 WO2002043731A2 (en) 2000-11-30 2001-11-30 Treatments for neurogenetic disorders, impulse control disorders, and wound healing

Country Status (7)

Country Link
US (3) US20020082222A1 (en)
EP (1) EP1345602B1 (en)
AT (1) ATE474572T1 (en)
AU (1) AU2002227052A1 (en)
CA (1) CA2430010A1 (en)
DE (1) DE60142632D1 (en)
WO (1) WO2002043731A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392273A1 (en) * 2001-05-14 2004-03-03 Brookhaven Science Associates Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
WO2008070670A2 (en) 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
WO2011069075A2 (en) 2009-12-04 2011-06-09 Grant Jon E Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
US9622983B2 (en) 2006-11-17 2017-04-18 Supernus Pharmaceutcals, Inc. Sustained-release formulations of topiramate
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US11096929B2 (en) * 2015-07-17 2021-08-24 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2021260667A3 (en) * 2020-06-26 2022-04-28 Universidade Do Minho Composition for hair follicle modulation, methods and uses thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2430010A1 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
WO2003097038A1 (en) * 2002-05-14 2003-11-27 Ralph Ryback Method for treating dermatoses and tissue damage
KR101813991B1 (en) 2008-06-12 2018-01-02 골지 피티와이 리미티드 Detection of hypokinetic and/or hyperkinetic states
RU2011120054A (en) * 2008-10-21 2012-11-27 Новодермикс Интернэшнл Лимитед COMPOSITIONS FOR TREATMENT OF EPITELIAL TISSUE
TWI570472B (en) * 2011-10-03 2017-02-11 三菱瓦斯化學股份有限公司 Aromatic polycarbonate polarized lens
TWI474831B (en) 2012-09-14 2015-03-01 Univ Taipei Medical Use of immunomodulatory protein in promotion of wound healing or treatment of tissue injury
WO2014131090A1 (en) * 2013-03-01 2014-09-04 Global Kinetics Corporation Pty Ltd System and method for assessing impulse control disorder
US10736577B2 (en) 2014-03-03 2020-08-11 Global Kinetics Pty Ltd Method and system for assessing motion symptoms

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US892088A (en) * 1907-09-26 1908-06-30 William Rich Marine fire-indicating system and extinguisher.
US5705477A (en) * 1982-09-24 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Compositions of transforming growth factor β(TGF-β) which promotes wound healing and methods for their use
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5571521A (en) * 1984-01-16 1996-11-05 Lasker; Sigmund E. Composition containing silver ammonium phenytoin complex and a phenytoin and use of said composition
US5856245A (en) * 1988-03-14 1999-01-05 Nextec Applications, Inc. Articles of barrier webs
US5632727A (en) * 1988-10-03 1997-05-27 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
GB9102660D0 (en) * 1991-02-07 1991-03-27 Ultra Lab Ltd Wound dressing materials
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5981606A (en) * 1991-03-01 1999-11-09 Warner-Lambert Company Therapeutic TGF-beta-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5662924A (en) * 1991-03-21 1997-09-02 Smith & Nephew Plc Wound dressing
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US5804213A (en) * 1991-10-09 1998-09-08 Lectec Corporation Biologically active aqueous gel wound dressing
AU3057792A (en) * 1991-11-06 1993-06-07 Bioderm, Inc. Occlusive wound dressing and applicator
US5376376A (en) * 1992-01-13 1994-12-27 Li; Shu-Tung Resorbable vascular wound dressings
USRE36370E (en) * 1992-01-13 1999-11-02 Li; Shu-Tung Resorbable vascular wound dressings
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
JP3550685B2 (en) * 1992-04-21 2004-08-04 味の素株式会社 Wound healing agent
EP0648113A4 (en) * 1992-04-23 1996-12-04 Berlex Lab Bioadhesive solid mineral oil emulsion.
GB9212303D0 (en) * 1992-06-10 1992-07-22 Johnson & Johnson Medical Ltd Absorbent products
GB2272645B8 (en) * 1992-11-23 2010-02-10 Johnson & Johnson Medical Wound dressing
GB9225581D0 (en) * 1992-12-08 1993-01-27 Courtaulds Plc Wound dressings
US5902600A (en) * 1992-12-21 1999-05-11 Healthpoint, Ltd. Hydrogel polymer wound dressing
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
GB2275686B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Swellable wound dressing materials
GB2275685B (en) * 1993-03-03 1997-04-30 Johnson & Johnson Medical Water soluble wound dressing materials
US5960795A (en) * 1993-07-16 1999-10-05 Tecnol Medical Products, Inc. Wound covering device
ATE210677T1 (en) * 1993-09-24 2001-12-15 Univ Southern California THE USE OF ANGIOTENSIN III AND ITS ANALOGUES FOR TISSUE HEALING
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
WO1995008565A1 (en) * 1993-09-24 1995-03-30 The University Of Southern California Use of angiotensin ii analogs in tissue repair
US5603946A (en) * 1993-10-08 1997-02-18 Bristol-Myers Squibb Company Wound dressing
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5507775A (en) * 1994-01-21 1996-04-16 Progressive Surgical Products Inc. Tissue expansion and approximation device
DE69530914T2 (en) * 1994-02-17 2004-03-11 New York Blood Center, Inc. BIOLOGICAL BIOADHESIVE PREPARATIONS CONTAINING FIBRINE ADHESIVE AND LIPOSOMES, METHODS FOR THEIR PRODUCTION AND USE
WO1995028124A2 (en) * 1994-04-08 1995-10-26 Atrix Laboratories, Inc. An adjunctive polymer system for use with medical device
US5522794A (en) * 1994-06-16 1996-06-04 Hercules Incorporated Method of treating human wounds
US5685834A (en) * 1994-07-29 1997-11-11 Barth; Alan H. Surgical dressing material
US5512041A (en) * 1994-10-07 1996-04-30 Scott Health Care Wound dressing for promoting moist wound healing
US5519020A (en) * 1994-10-28 1996-05-21 The University Of Akron Polymeric wound healing accelerators
WO1996022753A1 (en) * 1995-01-26 1996-08-01 Innovative Technologies Limited Wound dressing
EP0805663B1 (en) * 1995-01-27 2000-08-02 Coloplast A/S A dressing having a three-dimensional part and processes for the preparation of such a dressing
US5876743A (en) * 1995-03-21 1999-03-02 Den-Mat Corporation Biocompatible adhesion in tissue repair
US5578022A (en) * 1995-04-12 1996-11-26 Scherson; Daniel A. Oxygen producing bandage and method
US5690795A (en) * 1995-06-05 1997-11-25 Applied Materials, Inc. Screwless shield assembly for vacuum processing chambers
US5834432A (en) * 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
EP0830381A4 (en) * 1995-06-09 2000-11-22 William N Drohan Chitin hydrogels, methods of their production and use
US6087549A (en) * 1997-09-22 2000-07-11 Argentum International Multilayer laminate wound dressing
US5892088A (en) * 1995-11-02 1999-04-06 Yukong Limited Sulfamate compound containing N-substituted carbamoyl group and method for preparing the same
KR970027051A (en) * 1995-11-02 1997-06-24 조규향 Novel Sulfamate Compounds Containing Carbamoyl Groups
GB9523253D0 (en) * 1995-11-14 1996-01-17 Mediscus Prod Ltd Portable wound treatment apparatus
AU725654B2 (en) * 1996-05-03 2000-10-19 Innogenetics N.V. New medicaments containing gelatin cross-linked with oxidized polysaccharides
US5968001A (en) * 1996-05-14 1999-10-19 Bristol-Myers Squibb Company Wound dressings with leak prevention seal
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
EP0915697B1 (en) * 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
DK0964681T3 (en) * 1996-06-28 2001-10-08 Ortho Mcneil Pharm Inc Anticonvulsant derivatives for the treatment of psoriasis
US6093388A (en) * 1996-08-12 2000-07-25 Btg International Limited Mannose-6-phosphate composition and its use in treating fibrotic disorders
US6033684A (en) * 1996-08-28 2000-03-07 Jonor, Inc. Compositions and methods for wound management
US5807300A (en) * 1996-09-20 1998-09-15 Nix, Jr.; Frank H. Holder for wound dressing
US5897516A (en) * 1996-09-27 1999-04-27 Bristol-Myers Squibb Company Method of treating a wound by monitoring the swelling of a hydrocolloid layer in a wound dressing
NZ334981A (en) * 1996-10-08 2000-08-25 Ortho Mcneil Pharm Inc Anti-convulsant derivatives such as topiramate for treating neuropathic pain
US6025150A (en) * 1996-11-21 2000-02-15 The Regents Of The University Of Michigan Methods and compositions for wound healing
US5807341A (en) * 1996-12-11 1998-09-15 Team Medical Llc Medical catheter dressing device
US5977428A (en) * 1996-12-20 1999-11-02 Procyte Corporation Absorbent hydrogel particles and use thereof in wound dressings
US5780048A (en) * 1997-03-20 1998-07-14 Lee; Chung Chih First aid bandage dressing system and method of application thereof
US5972332A (en) * 1997-04-16 1999-10-26 The Regents Of The University Of Michigan Wound treatment with keratinocytes on a solid support enclosed in a porous material
US5760006A (en) * 1997-06-23 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating psoriasis
US6136341A (en) * 1998-02-27 2000-10-24 Petito; George D. Collagen containing tissue adhesive
US5989577A (en) * 1998-03-02 1999-11-23 Children's Hospital Medical Center Nontoxic vernix compositions and method of producing
WO2000000130A1 (en) 1998-06-29 2000-01-06 The Procter & Gamble Company Liquid transport member for high flux rates against gravity
WO2000010610A2 (en) 1998-08-19 2000-03-02 Theramark Limited Drug targeting
AU759756B2 (en) * 1998-10-20 2003-05-01 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse
ES2217819T3 (en) * 1998-11-17 2004-11-01 Ortho-Mcneil Pharmaceutical, Inc. ANTI-CONVULSIVE DERIVATIVES FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDERS.
HUP0105420A3 (en) 1999-02-01 2003-03-28 Ortho Mcneil Pharm Inc Use of anticonvulsant derivatives for treating bulimia nervosa
EP1158950B1 (en) * 1999-02-17 2006-01-25 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating essential tremor
PT1158973E (en) * 1999-02-24 2005-07-29 Univ Cincinnati USE OF SULFAMATE DERIVATIVES FOR THE TREATMENT OF DRIVE CONTROL DISTURBLES
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
ES2542868T3 (en) * 1999-06-14 2015-08-12 Vivus, Inc. Combination therapy for the treatment of diabetes associated with obesity
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2430010A1 (en) * 2000-11-30 2002-06-06 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
WO2003097038A1 (en) * 2002-05-14 2003-11-27 Ralph Ryback Method for treating dermatoses and tissue damage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392273A4 (en) * 2001-05-14 2004-11-24 Brookhaven Science Ass Llc Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
EP1392273A1 (en) * 2001-05-14 2004-03-03 Brookhaven Science Associates Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg
WO2004050081A1 (en) * 2002-12-02 2004-06-17 University Of Florida Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US7208477B2 (en) 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
US9744137B2 (en) 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
US10314790B2 (en) 2006-11-17 2019-06-11 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US9622983B2 (en) 2006-11-17 2017-04-18 Supernus Pharmaceutcals, Inc. Sustained-release formulations of topiramate
WO2008070670A2 (en) 2006-12-04 2008-06-12 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
WO2008070670A3 (en) * 2006-12-04 2009-02-05 Supernus Pharmaceuticals Inc Enhanced immediate release formulations of topiramate
EP2363113A1 (en) * 2006-12-04 2011-09-07 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
AU2007329373B2 (en) * 2006-12-04 2013-06-20 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
WO2011069075A2 (en) 2009-12-04 2011-06-09 Grant Jon E Treating impulse control disorders with catechol-o- methyl-transferase inhibitors
US8598235B2 (en) 2009-12-04 2013-12-03 Jon E. Grant Treating impulse control disorders with catechol-O-methyl-transferase inhibitors
US11096929B2 (en) * 2015-07-17 2021-08-24 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2021260667A3 (en) * 2020-06-26 2022-04-28 Universidade Do Minho Composition for hair follicle modulation, methods and uses thereof

Also Published As

Publication number Publication date
US20020082222A1 (en) 2002-06-27
US20050101543A1 (en) 2005-05-12
US8084491B2 (en) 2011-12-27
CA2430010A1 (en) 2002-06-06
WO2002043731A3 (en) 2003-02-20
EP1345602A2 (en) 2003-09-24
EP1345602B1 (en) 2010-07-21
AU2002227052A1 (en) 2002-06-11
US20080021094A1 (en) 2008-01-24
WO2002043731B1 (en) 2003-04-03
DE60142632D1 (en) 2010-09-02
ATE474572T1 (en) 2010-08-15

Similar Documents

Publication Publication Date Title
US8084491B2 (en) Treatments for wound healing
ES2349862T3 (en) WOUND HEALING.
Shelton et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs
EP0491094B1 (en) Felbamate for treating Lennox-Gastaut syndrome
DE69821123T2 (en) DIET COMPOSITION TO INCREASE METABOLISM AND REDUCE OXYDATIVE STRESS
US20080249082A1 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity and Impulsivity
US20040029941A1 (en) Zonisamide use in obesity and eating disorders
US20210030665A1 (en) Synthetic transdermal cannabidiol for the treatment of focal epilepsy in adults
FR2559061A1 (en) ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS CONTAINING DIPHENHYDRAMINE
CA2445528A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
JP2005518439A (en) Co-therapeutic agent for the treatment of migraine comprising an anticonvulsant derivative and an anti-migraine agent
EP0616804A1 (en) Gamma-hydroxybutyric acid salts possessing anxiolytic activity and suitable for the treatment of states of depression
JP6200561B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
KR20230031317A (en) Treatment of Fragile X Syndrome with Cannabidiol
CN115803019A (en) Treatment of autism spectrum disorders with cannabidiol
CA3212035A1 (en) Methods and compositions for treating sleep apnea
US11660279B2 (en) Therapeutic agents for treating restless leg syndrome
JP2019514978A (en) Treatment of alcoholism and depression and / or unpleasant mood using ibudilast
AU2011235981B2 (en) Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity
AU2002307542A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2430010

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001996012

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001996012

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP